Categories
Report

(NASDAQ: SVRE)

SaverOne Logo

READ THE INVESTOR PRESENTATION HERE

__________________________________

Hello Everyone,

We have one last profile to close the year out. This year has been incredible for some of our members. We definitely have profiled our fair share of losers this year, nobody has ever batted 1000. With that being said, we have definitely seen a gang of double and triple digit movers.

For Fridays session we are bringing back a company that we profiled heading into 2023 and it went on a 8 week 200% move into January of this year.

We want you to put SVRE back on the screen.

Before we get down to business we just wanted to congratulate our members who have been following KULR along with us over he past few years. We have brought you this one no less than 10 times over the past few years and as recently as just 2 weeks ago. The company has been releasing huge news over the past few years and today the faithful struck proverbial oil with this one busting out and almost breaking the $5 mark, hitting 4.94 before the close.

We have profiled this one when it was below .20 just a few months back. That’s like a 2000% move if you were a real believer in this one a company. We looked at it in March, April, June, September, November and December. We don’t often see this happen but where we have covered this one so many times for our members in the past, we thought it was worthy of updaditing you guys on.

Speaking of MASSIVE days, let’s get back to SVRE for a minute.

Something is definitely going on with his one

On Christmas eve SVRE closed 63% and hit 1.59 on way above average interest.

Wednesday it dipped back below a buck and closed at 1.06 on about $1.5 of the $2.5 the previous session.

We think that there is a lot of support now at this $1 level but we certainly shall see what happens. There is certainly know way of knowing for sure.

Founded in 2014 with a mission to make roads safer for drivers, passengers, and pedestrians alike, SaverOne develops cellular network-based technological solutions for reducing road accidents.

their innovative system for identifying and limiting the use of certain apps on mobile devices while operating a vehicle has already been widely adopted by dozens of companies in Israel.

SaverOne is also developing an additional system that can detect and warn the driver of VRU’s (Vulnerable Road Users and pedestrians) crossing when the driver’s field of vision is extremely limited. This system is currently in advanced stages of development.

Located in Israel, the company currently employs over 50 employees in its research and development, sales, business, operations, and support departments.

This one has traded on the NASDAQ since 2020 (TASE: SVRE Nasdaq: SVRE)

SaverOne’s product portfolio addresses two main automotive segments:

  • After-market segment: protecting existing cars, trucks, and buses; working with vehicle fleets.
  • Pre-Market OEM segment: integrating SaverOne’s Protection technology in the vehicle assembly line.

SaverOne’s system is installed in vehicles to provide a solution to the problem of driver distraction, as a result of drivers using distracting applications on the mobile phone while driving, in a way that endangers their safety and the safety of their passengers. This phenomenon is considered one of the main causes of road accidents in the world. According to the US National Highway Traffic Safety Administration, the annual cost of road accidents just in the United States, stands at about $870 billion each year, excluding the costs of serious injury or death, with a quarter of those accidents estimated to be related to the use of the mobile phones while driving. SaverOne’s technology specifically recognizes the driver area in the vehicle and prevents the driver from accessing distracting applications such as messaging, while allowing others (e.g. navigation), without user intervention or consent, creating a safer driving environment.

SaverOne’s primary target markets include commercial and private vehicle fleets that are interested in reducing potential damages and significant cost, vehicle manufacturers that are interested in integrating safety solutions to their vehicles, and insurance and leasing companies. SaverOne initially addresses car fleets with focus on the Israeli, European and US markets, as well as other markets around the world. SaverOne believes that ultimately increased focus on monitoring and prevention of cellular distraction systems in vehicles, in particular driven by upcoming expected EU regulation, will likely have a dramatic positive impact on the demand for its systems in the future.

The Company’s strategy is to provide its technology for installation to customers in the aftermarket as well as address OEM vehicle manufacturers, to install the Company’s protection technologies during the vehicle manufacturing process.

SaverOne Continues to Expand its Global Reach with New Distribution Agreement with Smartfits in the UK

Petah Tikvah, Israel, Dec. 17, 2024 (GLOBE NEWSWIRE) —  SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a technology company that develops and sells advanced transportation safety solutions, today announced it has signed a new distribution agreement with Smartfits Installations Ltd. (Smartfits) to bring its driver distraction prevention technology to fleets across the United Kingdom.

Smartfits, based in Burton on Trent, central England, specializes in fleet safety and technology integrations, serving a diverse range of industries including logistics, public transport and corporate fleets.

Mr. Ori Gilboa, CEO of SaverOne, commented, “We are excited to partner with Smartfits as we introduce our critical road-safety technology to the UK market. This new partnership reflects Smartfits’ commitment to introducing cutting-edge safety innovations to its customer base and aligns strongly with our mission of enhancing road safety. This new distribution partnership is part of our strategic global expansion plan and builds on our strong recent success in European markets. Smartfits’ expertise and focus on delivering safety-driven solutions to fleet operators makes them an ideal partner. We believe their deep market knowledge and strong distribution capabilities will enable us to address the significant potential demand for driver distraction prevention technology in the UK.”

Ms. Lehanne Hassall, Head of Operations at Smartfits, added, “We are thrilled to build this new collaboration with SaverOne and bring their pioneering solution to customers across the UK. Fleet safety is a top priority for operators, and SaverOne’s technology offers an innovative way to prevent distractions and reduce accidents. Together, we aim to make British roads safer while helping fleets achieve greater efficiency and compliance. We anticipate strong market demand ahead as we launch the product into the UK market and look forward to providing fleets with this groundbreaking technology.”

The UK fleet market, with over five million vehicles, has potential for growth in safety-enhancing technologies, driven by increasing regulatory focus and the rising costs of accidents caused by driver distractions. SaverOne’s solution directly addresses these challenges by preventing mobile phone distractions among drivers, thereby reducing risks and operational costs for fleet operators.

SaverOne Launches New Pilot Project in Italy with Trans Italia

Trans Italia is a Leading Logistics & Transportation Company Operating Over 300 Trucks

Petah Tikvah, Israel., Dec. 09, 2024 (GLOBE NEWSWIRE) — SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a technology company that develops and sells advanced transportation safety solutions, is pleased to announce the launch of a new pilot project with Trans Italia, a prominent Italian logistics and transportation company well known for its eco-friendly, efficient, and intermodal transport solutions throughout Italy and beyond. This pilot marks a further and significant step in SaverOne’s expansion into the Italian market and its broader European growth strategy.

The pilot project involves the installation of SaverOne’s innovative driver safety system in an initial group of Trans Italia’s trucks. This initiative will demonstrate the system’s ability to prevent distractions while driving and highlight its potential to enhance road safety. With a fleet of over 300 trucks, Trans Italia offers substantial growth potential for SaverOne and provides a strategic platform to showcase its technology to the Italian logistics and eco-friendly transport sectors.

This collaboration was made possible through SaverOne’s Italian partner, Mr. Tal Yhie, and its regional distributor, GVZ Components. The installations are being carried out in partnership with TBS, SaverOne’s installation partner in the region, establishing a foundation for expanding installation capacity throughout Italy.

“This pilot project with Trans Italia demonstrates our increase in traction within Italy,” said Ori Gilboa, CEO of SaverOne. “We are thrilled to collaborate with a forward-thinking company like Trans Italia to demonstrate the value of our technology in improving the safety of their fleet and reducing distracted driving amongst their drivers. We believe this pilot will pave the way for increased adoption of our solutions within Italy and across Europe.”

Sergio Rotondo, Trans Italia’s Fleet Manager added, “Safety is a core value for Trans Italia, and we are committed to adopting innovative technologies that help us achieve that goal. SaverOne’s system aligns perfectly with our mission to enhance the safety of our drivers, our fleet, and the communities we serve. We are excited to see the impact of this pilot project and look forward to a long-term and successful collaboration with SaverOne.”

SaverOne Launches a New Pilot Project with a Leading Italian Sports Car Manufacturer

Petah Tikvah, Israel., Dec. 03, 2024 (GLOBE NEWSWIRE) — SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a technology company that develops and sells advanced transportation safety solutions, is pleased to announce the launch of a new pilot project with a globally renowned Italian luxury and sports car manufacturer.

The pilot project involves the installation of SaverOne’s distracted driving prevention system in an initial group of employee vehicles, potentially a first step in the installation of SaverOne’s systems across the manufacturer’s broader employee fleet of approximately 200 vehicles.

This new pilot marks a milestone for SaverOne, highlighting SaverOne’s further growing momentum in the Italian market. Following strong recent traction in the Italian market, it demonstrates a further successful step in SaverOne’s European expansion strategy and its commitment to enhancing road safety and driving adoption of its cutting-edge technology.

SaverOne’s growth into the Italian market is being led together with SaverOne’s Italian partner, Mr. Tal Yhie, and SaverOne’s regional distributor, GVZ Components.

Ori Gilboa, CEO of SaverOne, commented, “This new customer’s decision to launch a pilot of SaverOne’s safety system has immense potential. As a leading sports car manufacturer, their endorsement is a powerful validation of our technology and its ability to address a critical global challenge – distracted driving caused by cellphones. By adopting SaverOne’s technology, this customer is not only demonstrating its reputation for excellence and innovation but also its leadership in driver safety.”

Continued Mr. Gilboa, “This pilot is a testament to our expanding traction in Italy. We are confident this pilot will lead to new opportunities with other automotive manufacturers exploring state-of-the-art safety solutions.”

SaverOne Reports First Half 2024 Results

PETAH TIKVAH, Israel, Aug. 27, 2024 (GLOBE NEWSWIRE) — SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a company developing and deploying transportation safety and advanced driver-assistance systems (ADAS) technologies and solutions, today presented its results for the first half ended June 30, 2024 and shared recent business updates.

Recent Highlights

  • Significant reduction in first half operating expenses of NIS 2.3 million ($612 thousand), reducing operating loss and cash burn;
  • 4,800 systems have been ordered by customers as of August 26, 2024, of which approximately 3,750 have been installed;
  • OEM Agreement Signed with Volvo Group to install SaverOne Systems during the manufacturing process in Volvo Buses in Mexico;  
  • OEM Agreement Signed with IVECO to develop a software-as-a-service solution to prevent driver distraction from cellphone use, with first IVECO vehicles with integrated SaverOne software solution expected to be delivered in early 2025;
  • Announced spinoff to advance development on the VRU Sensor Solution with estimated annual market potential of $1.5 billion by 2035;
  • Purchase order from IVECO for a proof-of-concept (POC) for the VRU sensor for their Advanced Driver-Assistance System (ADAS);
  • Launched a number of pilot projects for fleets in the United States, Latin America and Europe.

Financial Highlights

  • Revenues of NIS 483 thousand (~$129 thousand) in the first half of 2024 versus NIS 1.5 million (~$395 thousand) in the first half of 2023;
  • Operating expenses reduced to NIS 15.8 million ($4.2 million) in the first half of 2024 versus NIS 18.1 million ($4.9 million) in the first half of 2023;  
  • Net loss reduced to NIS 16.3 million (~$4.4 million) in the first half of 2024 versus NIS 17.8 million in the first half of 2023 (~$4.8 million);
  • June 30, 2024 cash and cash equivalents of NIS 11.3 million (~$3.0 million).

Management Comment

Commented Mr. Ori Gilboa, CEO of SaverOne, “2024 has been challenging for SaverOne due to longer sales cycles in our home market of Israel. On the positive side, we are witnessing a broadening of our activities internationally through our partners, OEMs and new regional distributors. We are working to expand our global footprint with key existing customers by penetrating their international subsidiaries. We have also initiated new pilot projects in the United States, Europe and Latin America and have also secured initial commercial orders. International expansion requires significant effort, and in 2024, we have made substantial progress in establishing SaverOne as a global business. We remain optimistic and expect a renewed growth trend in the coming months.”

Continued Mr. Gilboa, “During the quarter, we announced our plans for a spinoff company focused on advancing our VRU (Vulnerable Road User) sensor solution, which represents a significant opportunity for us. This decision was based on a comprehensive analysis by a world leading consultancy firm, which estimated the addressable annual market potential for our VRU product at $1.5 billion by 2035. Additionally, we received a new purchase order for a proof-of-concept (POC) from IVECO to integrate our VRU sensor into their Advanced Driver Assistance System (ADAS), further enhancing vehicle safety. We believe that our VRU presents significant value for SaverOne long-term.”

Recent Developments in the First Half of 2024

  • SaverOne to Install its System Across Entire Strauss Group Fleet. Strauss Group is one of the largest food manufacturers in Israel with a fleet of over 80 food delivery trucks. The new order covering the entire Strauss delivery fleet, follows a successful trial on 17 Strauss trucks, in which Strauss’ management noted a statistically significant reduction in accident rates in the trucks that had the SaverOne system installed.
  • SaverOne Signed Contract to Install its Systems on 300 Buses of Leading Israeli Transportation Company Bon Tour.  Bon Tour is one of the leading private transit companies in Israel, operating hundreds of buses and providing transportation solutions and travel services to some of the largest companies in the country.  
  • Leading Israeli Transportation Company Egged Tours Selects SaverOne’s Driver Distraction Solution System for a contract to install 300 SaverOne Systems on all of its buses. Egged Tours, operating the largest tour bus fleet in Israel, is a subsidiary of Egged Transportation, Israel’s largest bus company, with over 3,000 buses operating nationally with a vast network of urban and intercity routes.  
  • SaverOne Granted New US Patent Strengthening its IP portfolio Supporting its Transportation Safety Solution. This marks SaverOne’s 23rd patent and describes SaverOne’s advanced algorithms and its selective blocking mechanism to prevent the driver from accessing distracting phone functionalities while the vehicle is in motion.  
  • SaverOne Launches New Pilot Project in the United States with Motor Supply, Inc., a trucking company based in Columbia, South Carolina. SaverOne’s System was installed on a portion of Motor Supply’s fleet of sixteen trucks. The pilot is expected to run over a period of 12 months and, if successful, could potentially expand to the rest of the fleet and any future trucks that Motor Supply may operate.
  • GB Tours to Expand its Installation of the SaverOne System Across its Full Fleet of Public Transportation and Tour Buses. GB Tours is a leading Israel-based public transportation company that operates public transportation lines as well as tour buses with a fleet of about one hundred buses. This order for 77 buses follows the conclusion of a successful pilot of the SaverOne System on 20 of GB Tours’ buses.
  • OEM Agreement Signed to Install the SaverOne Safety Solution in Volvo Buses in Mexico. SaverOne’s Safety Solution will be installed in new Volvo buses that are manufactured for the Mexican market. The agreement provides Volvo with two years of exclusivity in the OEM market in Mexico. SaverOne will also provide twelve months of service and support for Volvo bus customers. After that period, Volvo bus customers will continue to receive SaverOne’s comprehensive service package for an on-going monthly fee.
  • SaverOne Signs Milestone OEM Agreement with IVECO to develop a solution to prevent driver distraction from cellphone use. The first IVECO vehicles with the integrated SaverOne software solution are expected to be delivered this year. IVECO and SaverOne will also collaborate within their service centers to offer comprehensive support for drivers that use this technology. SaverOne’s solution will be provided to IVECO’s customers under a software-as-a-service model.    
  • SaverOne Expands its Collaboration with IVECO with its Vulnerable Road User Solution. Receives New Purchase Order for a vulnerable road user (VRU) proof-of-concept (POC). The POC will present SaverOne’s radio frequency (RF)-based solution that could be integrated in the vehicle Advanced Driver Assistance System (ADAS) to enhance vehicle safety. This solution is expected to be installed in one of IVECO’s vehicles in Europe in early 2025.
  • SaverOne Granted New European Patent encompassing SaverOne’s innovative system and groundbreaking methods that employ machine learning and channel fingerprinting techniques.
  • SaverOne: External Analysis Projects Annual $1.5 Billion Market Potential by 2035 for its RF-ADAS Technology.  Announced spinoff company dedicated to advancing VRU sensor solution following the conclusion of a comprehensive project completed by a leading global consultancy firm which analyzed the addressable market potential, as well as the initial interest from OEMs. The consultancy firm’s analysis projects a market potential annually of $1.5 billion by 2035.
  • Global Food Manufacturer Expands Installation of SaverOne Protection System. Follow-on order for 50 SaverOne Systems by the Israeli subsidiary of a leading global food manufacturer, for installation in their employee vehicles. This new order follows several successful trial phases and a prior order in November 2022, during which 80 employee vehicles in Israel were equipped with the SaverOne system.  
  • Global Food Manufacturer Adopts SaverOne System for Supply Chain Truck Protection. Following the successful completion of a pilot of SaverOne Systems’ on the customer’s trucks, an integral part of their supply chain in Israel, the customer ordered 46 SaverOne Systems. The customer is the Israeli subsidiary of one of the world’s top food manufacturers.
  • Egged Tours Broaden Installation of SaverOne System Across its Entire Bus Fleet.   The follow-on project will install the SaverOne system on an additional 60 buses  and cover Egged Tours’ entire fleet at its central hub of 130 vehicles. Egged Tours is a subsidiary of Egged Transportation, Israel’s largest public bus fleet with over 3,000 buses, representing significant broader sales potential for SaverOne.            

Financial Summary for the First Half of 2024

Revenues was NIS 483 thousand (~$129 thousand) in the first half of 2024 compared to NIS 1.5 million (~$395 thousand) for the first half of 2023. This decrease was mainly due to the longer decision-making processes by current and prospective customers in the home market of Israel.

Gross profit was NIS 85 thousand (~$23 thousand), representing gross margin of 18% in the first half of 2024 compared to NIS 467 thousand (~$124 thousand), representing gross margin of 32%, in the first half of 2023.

Research and development expenses, net were NIS 8.9 million (~$2.4 million) in the first half of 2024 compared to NIS 12.2 million (~$3.3 million) in the first half of 2023. This decrease is primarily attributable to our efforts to streamline and optimize our research and development expenses.

Selling and marketing expenses were NIS 2.4 million (~$640 thousand) in the first half of 2024 compared to NIS 1.4 million (~$385 thousand) in the first half of 2023. The increase is attributable mainly to higher marketing expenses in light of the Company’s efforts in expanding the business to international markets.

General and administrative expenses were NIS 4.5 million (~$1.2 million) in the first half of 2024, compared to NIS 4.5 million (~$1.2 million) in the first half of 2023.  

Operating loss was NIS 15.7 million (~$4.2 million) in the first half of 2024, reduced in comparison to NIS 17.6 million (~$4.7 million) in the first half of 2023, primarily as a result of efforts taken by the company to reduce expenses and ongoing cash burn.

Net loss in the first half of 2024 was NIS 16.3 million (~$4.4 million), reduced in comparison to NIS 17.8 million (~$4.8 million) for the first half of 2023.  

Cash and cash equivalents and short-term bank deposits as of June 30, 2024, amounted to NIS 11.3 million (~$3.0 million), compared with NIS 17.1 million (~$4.8 million) as of December 31, 2023. In July 2024, the Company secured an equity line amounting to $15 million.

The Company’s financial results are presented in accordance with IFRS as issued by the IASB.

*Unless otherwise noted, for the purposes of the presentation of financial data, all conversions from New Israeli Shekels (NIS) to U.S. dollars and from U.S. dollars to NIS were made at the rate of NIS 3.759 to $1.00, based on the representative exchange rate reported by the Bank of Israel on June 30, 2024

NEWS

SaverOne Continues to Expand its Global Reach with New Distribution Agreement with Smartfits in the UK

GlobeNewswire•9 days ago

SaverOne Launches New Pilot Project in Italy with Trans Italia

GlobeNewswire•17 days ago

SaverOne Launches a New Pilot Project with a Leading Italian Sports Car Manufacturer

GlobeNewswire•23 days ago

SVRE: Updating our model to reflect the recent ADS ratio adjustment.

Zacks Small Cap Research•last month

SaverOne signs a Commercial Agreement with a Leading Multinational in the Construction Sector

GlobeNewswire•last month

SaverOne Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire•last month

SaverOne Expands European Reach in Spain and Portugal through a New Distribution Agreement with Sistemas ADAS

GlobeNewswire•2 months ago

SaverOne Announces First Distribution Agreement in the United States

GlobeNewswire•2 months ago

SaverOne Announces New Pilot with Malta Public Transport Company

GlobeNewswire•3 months ago

SaverOne Launches Four Pilot Projects with Customers of Volvo Buses Mexico

GlobeNewswire•3 months ago

Froneri Israel Orders SaverOne Systems to Provide Safety Coverage for its Entire Fleet

GlobeNewswire•3 months ago

‍

MANAGEMENT  

Jacob Tennenbaum

Jacob Tennenbaum

Chairman

Jacob has decades of experience in management, entrepreneurship and investments, high-tech and venture capital.  He leads a large number of start-ups towards financial success.

Uri Gilboa

Ori Gilboa

CEO

Ori has extensive experience in managing companies with large volumes of activity in the automotive and retail industry. He served, among others, as the CEO of the Meir Group’s automotive division, the CEO of James Richardson, and the CEO of the Negev Group and more.

Yossi Cohen

Yossi Cohen

Founder and COO

Yossi brings more than 25 years of experience in the telecommunications and automotive industries. Combining in-depth business, operations and technical knowledge. Yossi has led global business, operational and technology activities over the past two decades.

Omri Hagai

Omri Hagai

CFO

Over 10 years of experience in the financial management of public companies.

Prior to SaverOne, Omri served as Director of Finance  for BrainsWay & Disclosure and Reporting Controller of Israel Chemicals.

Aviram Meidan

Aviram Meidan

VP of R&D

Aviram has technological experience in communications and in the interface with the automotive industry. He has over 20 years of experience in developing multidisciplinary systems and managing development groups.

Israel Eybi

Chief Marketing and Sales Officer

Over 25 years of experience in marketing, sales and business strategies.

Israel brings many years of key relevant and solid experience in the cellular IoT-automotive segments.

Prior to SaverOne, Israel served as Chief Customer Officer at the Bezeq Group, as well as Chief Customer Officer at Pelephone.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND FIVE HUNDRED USD BY SHORE THING MEDIA LLC FOR A ONE DAY SVRE AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

GAUZ

Gauzy was selected by Ferrari to supply its SPD smart glass technology to support the serial production of its first ever 4-seater offering for eight years

A major international airline contracts Gauzy for cabin shading with LCG® Smart Glass on Boeing 737 MAX fleet

They also just signed their largest-to-date Automotive serial production deal to deliver LCG® Smart Glass into an average of 50,000 cars per year for nine years with a major European OEM

For the first 9 months revenues increased 29% to an impressive $72.4 million

CHECK OUT THE INVESTOR PRESENTATION HERE

_________________________

Hello Everyone,

We keep talking about how exciting these times are right now. We have rates coming down, The Nasdaq up 32% YTD, Bitcoin just exploded through all time highs and the Russell 2000 which tracks small caps is up over 12% YTD and many are saying that it is just getting warmed up.

You don’t even have to look at any of that stuff to realize that we are in a bullish market and a stong economy. Just look at our recent profiles. We have recently profiled many double and triple digit movers in the past 60 days and thats just a fact. The receipts are time stamped and sitting in your inbox.

We have been looking at lot of AI and Biotech companies as of late but we want you to take a real strong look at this tech play.

Our new profile for Friday is GAUZ.

This company is brand new to us here. We have never profiled this company here and I have to say that we came across some exciting catalysts that have the potential to push this company forward in the years to come.

GAUZ is definitely not a one trick pony.

Gauzy is at the forefront of innovation, redefining how multi-billion-dollar industries operate with its groundbreaking technologies. From AI-powered Advanced Driver Assistance Systems (ADAS) revolutionizing road safety to visionary solutions transforming aeronautics and automotive design, this company is pushing the limits of what’s possible in light and vision control.

The company concentrates their efforts on three main segments, all of which are generating revenues:

  • Architecture and Automotive: Providing smart glass technologies for buildings and vehicles, including next-gen digital displays, glass rooftops, side windows, and windshields, to replace conventional sun visors and shades.
  • Safety Tech: Offering Advanced Driver Assistance Systems (ADAS) for buses, semi-trucks, tractors, and construction vehicles, such as AI powered camera monitor and motion sensor systems, and safety doors
  • Aeronautics: Supplying smart glass, traditional shading, and cabin management systems for private and commercial aircraft, as well as helicopters.

These diversified revenue streams, supported by 83.1% recurring revenue from long-term contracts, create a solid foundation for Gauzy’s sustained growth.

You have most likely encountered Gauzy’s handiwork in your everyday life and not even known it. They are already doing business with some of the biggest corporations on the planet and most recently were selected by the most iconic automobile manufacturer in the world to supply their new venture for the next 8 years.

You will see that GAUZ has been up to a lot lately if you take a real deep dive into the company like I have over the past 48 hours. We don’t have to look far back to see that GAUZ is moving forward as a company and most importantly they are signing deals and securing revenues.

Let’s take a brief look at what they have accomplished in JUST the last quarter:

  • Yutong, the world’s largest bus OEM, increased third quarter orders by 250% year-over-year, positioning Gauzy to extend its global share of buses using its Smart-Vision ADAS
  • Signed their largest-to-date Automotive serial production deal to deliver our LCG® Smart Glass into an average of 50,000 cars per year for nine years with a major European OEM
  • Gauzy selected by Ferrari to supply its SPD smart glass technology to support the serial production of its first ever 4-seater offering for eight years
  • A major international airline contracts Gauzy for cabin shading with LCG® Smart Glass on Boeing 737 MAX fleet
  • Selected by one of the largest cruise ship manufacturers to supply new terminal in Miami, Florida with over 11,000 sqft of LCG® Smart Glass Transparent Display Façade

Pretty impressive right? But what about the numbers? What about the meat and potatoes?

Well, those are pretty impressive too but I’ll let you be the judge of that.

Revenues for the first three quarters are up 30% year-over-year, and its gross profits are up 34%.

‍Third quarter revenues were $23.3 million. They increased 24.6% compared to $18.7 million in the prior year quarter.  The impressive jump were a result of existing and new customer accounts in the Safety Tech and Architecture divisions.

For the first 9 months of the year GAUZ saw Revenues of $72.4 million, which increased 29.2% compared to $56.0 million.

They are well funded too. As of September 30, 2024, the Company had total liquidity of $44.4 million, including $9.4 million of cash and cash equivalents and $35.0 million of available capacity under its undrawn credit line.

Gauzy’s vision control systems are equipping cities around the world to focus on increasing public & road safety.

Its Smart-Vision® ADAS, already replacing traditional mirrors on public buses in Paris ahead of the 2024 Olympics and in New York through CDTA’s transit program, are revolutionizing road safety by reducing blind spots and enhancing driver awareness.

These solutions are now deployed in over 80 cities worldwide, with continued expansion underway.

With smart glass technology rapidly gaining adoption across luxury and mass-market vehicles, including inclusion in McLarens, Mercedes’, Cadillacs, and now Ferrari, Gauzy is poised to capture a growing share of the $12.3 billion automotive smart glass market.

‍
Simultaneously, Gauzy’s Smart-Vision® CMS is advancing vehicle safety through ADAS solutions, replacing traditional mirrors with state-of-the-art camera and display technologies.

Whether in public transportation, passenger vehicles, aviation, or groundbreaking architectural applications, Gauzy’s ability to replace traditional materials with smart, digitized solutions ensures its position as a key player in the industries of tomorrow, today

In September, company insiders including the CEO, CTO and CFO, as well as a long-term investor purchased nearly 50,000 shares of GAUZ stock.  

CEO Eyal Peso commented, “Our strong orderbook, pipeline of exciting new technologies and expanding market presence position us well for continued success. We are excited about our future and the opportunity to increase our ownership stake in Gauzy at attractive levels.”

What are the analysts saying?

Gauzy’s growth potential hasn’t gone unnoticed by industry analysts. With an average price target of $16.25, Gauzy continues to gain recognition as a leader in a rapidly expanding market.

‍

The company’s strong financial performance and market consensus underscore its unparalleled  innovation pipeline and strategic positioning in high-growth sectors.

Gauzy Ltd. Announces Purchases of Gauzy Shares by CEO, Other Senior Executives and Key Long-Term Investor

PUBLISHED

SEP 12, 2024 7:00AM EDT

TEL AVIV, Israel, Sept. 12, 2024 (GLOBE NEWSWIRE) — Gauzy Ltd. (Nasdaq: GAUZ) (“Gauzy” or the “Company”), a global leader in vision and light control solutions, today announced Eyal Peso, Co-Founder and Chief Executive Officer; Adrian Lofer, Co-Founder and Chief Technology Officer; Meir Peleg, Chief Financial Officer; and pre-IPO Gauzy Board member and long-term investor Alejandro Weinstein have acquired an aggregate of 48,472 Gauzy ordinary shares. The purchases, made at an average price of $10.35/share, for a total investment of $501,400, were made through open market purchases during the months of August and September 2024.

“This investment by core current and former leaders of Gauzy underscores our unwavering commitment and belief in our company’s vision and potential,” Mr. Peso stated. “Our strong orderbook, pipeline of exciting new technologies and expanding market presence position us well for continued success. We are excited about our future and the opportunity to increase our ownership stake in Gauzy at attractive levels.”

Ferrari Selects Gauzy’s Smart Glass Technology for Serial Production in Its First-Ever SUV

PUBLISHED

OCT 23, 2024 8:00AM EDT

Light control technology company becomes strategic supplier for iconic car manufacturer

Gauzy’s Suspended Particle Device (SPD) LCG® available in panoramic roofs on Ferrari’s premium SUV

Marks first time Ferrari has implemented smart glass technology on a mass production level for any of its automotive designs

NEW YORK and TEL AVIV, Israel, Oct. 23, 2024 (GLOBE NEWSWIRE) — Gauzy Ltd. (Nasdaq: GAUZ) (“Gauzy” or the “Company”), a global leader in light and vision control technology, today announced that Ferrari has selected the Company to become a strategic supplier, resulting in Gauzy already beginning to serially produce its Suspended Particle Device (SPD) Smart Glass technology for the iconic car manufacturer’s prestigious SUV. Gauzy’s SPD light control glass (LCG®) is available in the panoramic roof of the SUV, marking the first-time Ferrari has implemented smart glass technology on a mass production level for any of its automotive designs.

“It’s a tremendous accomplishment that another world-renowned and innovative automotive brand has selected Gauzy to become one of their strategic suppliers. We are extremely proud that Ferrari, one of the most iconic and recognized car makers in the world, has selected Gauzy’s smart glass technology as a key feature of its first-ever SUV,” stated Eyal Peso, Co-Founder and CEO of Gauzy. “Ferrari’s decision to use our LCG® technology in a multi-year program is a testament to the quality, sophistication and innovative nature of our light control products. Having Ferrari become associated with Gauzy is the ultimate seal of approval for the work we are doing to enhance safety, comfort, and design in the automotive industry.”

Smart glass technology, like that which Gauzy specializes in, has been quickly gaining in popularity with both luxury and mass-market vehicle manufacturers around the world given its numerous benefits – i.e., comfort and convenience, safety, aesthetics, ease of maintenance, thermal comfort and more. As such, the total value of the global automotive smart glass market is expected to reach $12.3 billion in value by 2032. Gauzy aims to capture a significant portion of this accelerated growth due to its expertise in both SPD and Polymer Dispersed Liquid Crystal (PDLC) technologies and positive reputation amongst the most respected OEMs in the U.S. and abroad.

Peso added, “SPD technology continues to gain in popularity as more and more OEMs understand how it helps enhance the overall driving experience and vehicle infrastructure. In fact, in addition to Ferrari, it’s already included on sunroofs in McLarens, Mercedes and Cadillacs, and is expected to be widely adopted in mass-market cars in coming years. We believe that this presents a massive opportunity for us to expand our market share for smart glass in automotive and drive continued growth for this business division.”

Gauzy’s SPD LCG® sets a new standard for innovation in vehicles by prioritizing design, functionality and experience through technologically advanced materials, providing drivers and passengers with optimal comfort and better awareness of their surroundings. Unlike traditional sunscreens or mechanical shades that block/obstruct views, reduce head and/or cabin space and are hard to clean, Gauzy’s patented SPD LCG® uses an electrical voltage to change the transparency of the glass and reduce glare and heat from direct light exposure, thereby eliminating the need for shading systems altogether. The Company develops and manufactures SPD technology licensed from Research Frontiers, in which Gauzy has been a strategic investor since 2018.

Ferrari, the fourth-largest automaker by market capitalization, is amongst the latest automotive manufacturers to select Gauzy as a strategic supplier due to its proven track record in designing and delivering high-quality light and vision control products that substantially increase road safety, filter out up to 99% of light transmission and improve the driver and passenger experience. As such, owners and occupants of the Ferrari SUV outfitted with Gauzy’s SPD LCG® can expect to have greater visibility of the outside scenery and better control over cabin light and temperature, resulting in a safer and more dynamic and comfortable on-road experience.

‍

NEWS

Gauzy Receives Outstanding Supplier Award for Its Smart-Vision® Advanced Driver Assistance System (ADAS) From World’s Largest Commercial Bus Manufacturer, Yutong1 day agoGauzy Appoints Seasoned Public Company Executive and Director Lilach Payorski to Board of DirectorsDec 3, 2024Gauzy Ltd. to Present and Feature Advanced Driver Assistance System (ADAS) Equipped Bus at Barclays 15th Annual Global Automotive and Mobility Tech ConferenceNov 18, 2024Gauzy Ltd. Announces Third Quarter and Nine Months 2024 ResultsNov 12, 2024CEOs of Gauzy and Research Frontiers Participate in Joint Interview with Benzinga All AccessNov 6, 2024Gauzy Ltd. adds Second Production Shift in Europe to Meet Strong Global Demand; Releases Preliminary Third Quarter Revenue Range and Provides Fourth Quarter GuidanceOct 31, 2024Ferrari Selects Gauzy’s Smart Glass Technology for Serial Production in Its First-Ever SUVOct 23, 2024Gauzy’s Advanced Driver Assistance System (ADAS) Fully Replaces Traditional Side Mirrors on Capital District Transportation Authority of New York’s Public BusesOct 10, 2024Gauzy to Unveil Next Generation AI-Powered Advanced Driver Assistance System (ADAS) for Commercial Trucks at IAA TRANSPORTATION 2024Sep 16, 2024Gauzy Ltd. Announces Purchases of Gauzy Shares by CEO, Other Senior Executives and Key Long-Term Investor

Sep 12, 2024

‍

MANAGEMENT

‍

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND FIVE HUNDRED USD BY LFG EQUITIES CORP FOR A ONE DAY GAUZ AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

Today’s Biotech Went Wild Now Look at This One Too

(Today’s Chart)

Hello Everyone,

What exciting times it is to be a trader right now. There is so much buzz around this next administration and the anticipation of what will happen with the economy over the next 4 years. The Nasdaq and the S&P just smashed all time highs. Bitcoin is going wild. Traders are loading the alts. Rates are dropping.
I don’t know about you but I am all the way in right now. The last 60 days or so have been incredible.

The Russel 2000, which is the benchmark index for small caps is up 12% YTD and 15% over the past year. Look no further than today. Our Profile opened at 1.45 and exploded to 1.81 by around 1:30 in the afternoon for a clean 25% move in just a couple of hours.

You already know I am going to bring up the back to back triple digit winners we dropped on you earlier this month and what about just last week?

We gave you KULR one week ago today. Scroll up and you will see it. It opened at 1.28 that day and hit 2.64 today. 100%+ Move People. That’s the third one in a month. What is going on here? Not too bad right? Thats a dollar move on a dollar stock. Are you excited yet? We are excited about the market and beyond excited to bring back a past winner. I think that we were the first ones to profile this company and put it on the map last year. We have seen it make some big moves in the past. 

You are going to want to get this one at exactly 8 am. We are switching things up. This is probably what we will be doing from now on. 8 or 9 am releases. With that being said, email is slow and unreliable. The best way to get our profiles in a timely manner is to join our free text messaging service. You can unsubscribe at any time but I cannot emphasize enough how essential it is to get on this list if you are a fan of what we are doing here. 

See you guys tomorrow at 8am with a bouncy biotech to research!
Categories
Report

NLSP

‍

________________________

Hello Everyone,

There is no doubt that small caps are back.

We have been waiting for this moment.

The Russel 2000, which is the benchmark index for small caps is up 12% YTD and 15% over the past year.

If that isn’t proof enough just look at the companies we have profiled over the past 60 days.

We don’t need to look further than yesterday.

The Biotech that we brought to your attention Tuesday night closed at 1.37 that session. Yesterday it hit 1.81 after opening at 1.42 for a clean 25% move north during the session.  Keep watching that one, but we have a time sensitive situation that we want to bring to your attention for today’s session.

This one exploded double digits the last time we took a look at it.

Since the last time we looked at it the company completed a 1-40 reverse split, wiping the float down to a mere fraction of what it was.

Pull up NLSP right away.

NLSP is a clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs.

The global ADHD market is expected to reach over US$ 70 billion by 2032 growing significantly in the coming years, fueled by rising diagnosis rates and demand for innovative treatments. And amid this growing need, NLSP is making impressive progress with a promising drug that targets not only ADHD but also closely linked sleep-wake disorders.

Their lead candidate is Mazindol ER. This one is Phase 3-ready for ADHD as well as for narcolepsy, also targeting excessive daytime sleepiness—a major unmet need in worldwide that is projected to grow at nearly 10% annually.

With a proven safety profile from prior use as an appetite suppressant, Mazindol ER has the potential to move efficiently through the regulatory pipeline. NLSP has also positioned itself with a clean balance sheet, recently regaining full Nasdaq compliance and clearing all debt while raising $3.2M and with a 12-month cash runway and a binding terms sheet for a merger with Kadimastema, a larger company that has an executive team with experience taking products from the lab to the market.

IsletRx is Kadimastem‘s treatment for diabetes. IsletRx is comprised of functional pancreatic islet cells producing and releasing insulin and glucagon. IsletRx is intended to treat and potentially cure patients with insulin-dependent diabetes.

CNS disorders are a diverse group of conditions that include neurological, psychiatric, and substance abuse disorders. Their discovery platform currently focuses on single molecules that function through multiple mechanisms designed to target the complexity of the CNS disease state. They believe that this approach may potentially offer new treatment options for patients, including those who are refractory to currently available treatments. Their current focus is in the therapeutic areas of rare hypersomnia disorders (conditions characterized by excessive daytime sleepiness, or EDS, such as narcolepsy) and complex neurodevelopmental disorders. Their drug development pipeline features our lead product candidate, Quilience®, for the treatment of EDS and cataplexy associated with narcolepsy, and our follow-on drug candidate Nolazol®, for the treatment of ADHD.

COMPANY HIGHLIGHTS

  • Mazindol ER has successfully completed a Phase 2 trial, including OLE, for narcolepsy treatment: projected to be $4.5B annual market by 2027**
  • Orphan Drug Designation (ODD) granted in the US and Europe
  • AMAZE phase 3 program starting in July 2023, secured funding for current projects and existing operations through 2025. Development of Mazindol ER is in the spotlight for progression purposes, particularly for the treatment of EDS and cataplexy in adult patients who suffer from narcolepsy
  • Named Patient Program for patients suffering from idiopathic hypersomnia launched in target markets across Europe
  • Key Executive Leadership roles filled
  • Pipeline progressed and expanded with long-dated IP protections in major markets
  • Over 100 patents in over 140 countries including technology and application for a variety of diseases such as ADHD, Cancer Fatigue, Parkinson’s and more. Not to mention that several products are nearing the end of Phase 2 and approaching NDA filing
  • POLARIS: Mazindol ER Phase 2 Program in Narcolepsy, consisted of two US clinicaltrials approved by the FDA, met its primary endpoint with high statistical significance and demonstrated a favorable safety and tolerability profile. These results were promising, i.e, Sustained EDS and cataplexy improvements at all time points. OLE conclusions: 6-month OLD, displayed good subject participation (87%) and retention (11.5%)
  • Partnership with Université de Lausanne (UNIL) (preclinical projects), University of Berne (narcolepsy reserach), Swiss Narcoslpsy Network (narcolepsy reserach) ( (BVF Partners L.P (financial partnership)
  • Partnerships with Patient advocacy groups including Narcolepsy Network, The Narcolepsy Foundation, The Sleep Consortium, Hypersomnia Foundation, and Wake Up Narcolepsy

NLS Pharmaceutics CEO Issues Letter to Shareholders

PUBLISHED

DEC 11, 2024 7:30AM EST

ZURICH, SWITZERLAND / ACCESSWIRE / December 11, 2024 / NLS Pharmaceutics Ltd.(Nasdaq:NLSP)(Nasdaq:NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders:

Dear Valued Shareholders,

As we move forward with exciting developments at NLS, I want to update you on the significant progress we’ve made, key challenges we’ve overcome, and the strategic opportunities that lie ahead-especially as we approach the expected closing of our transformative merger with Kadimastem Ltd. (“Kadimastem”), an advanced clinical-stage company.

The DOXA Program

Over the past several months, we’ve made substantial progress with our Dual Orexin Receptor Agonist (DOXA) platform, which we believe holds considerable promise in addressing key challenges in the treatment of sleep and neurodegenerative diseases. Recently, we announced details around our preclinical program to evaluate two candidates, AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs designed to target both orexin-1 (OX1R) and orexin-2 (OX2R) receptors while concurrently inhibiting cathepsins. This unique approach aims to address the unmet therapeutic needs in narcolepsy and related neurological disorders.

The preclinical study is being conducted at the Centre for Neurological Research of Lyon(France), a world-class institution specializing in sleep and neurological research, and aims to evaluate the potential superiority of AEX compounds over existing therapies in the space by using an internationally validated orexin knockout (ORX-KO) mouse model of narcolepsy.While existing selective OX2R agonists have demonstrated efficacy in managing narcolepsy symptoms, DOXA are expected to surpass these benchmarks. By engaging both OX1R and OX2R receptors and addressing broader neurological pathways, AEX-41 and AEX-2 offer the potential for enhanced therapeutic outcomes, including greater wakefulness stability and improved sleep quality under real-world conditions.

Earlier in December, we shared preliminary results from this ongoing study of AEX-41 in narcolepsy models which suggested that the compound shows promise as a therapeutic agent for managing narcolepsy-related sleep-wake disturbances.

Key findings from the study included:

  • Wakefulness: Increased stability with fewer interruptions.
  • Slow-Wave Sleep (SWS): Reduced fragmentation and improved continuity.
  • REM Sleep: Significant reduction in pathological episodes.

Final top line results from the ongoing study are expected to be shared by the end of this year. In addition, the Company’s broader development plans include exploring the application of its DOXA platform also in other neurodegenerative conditions, such as Amyotrophic Lateral Sclerosis (ALS).

Overcoming Obstacles

Despite significant challenges over the past few months, we have successfully positioned NLS for the next phase of growth:

– Financial growth and Nasdaq Compliance: After a period of risk regarding our Nasdaq listing, we are pleased to have regained full compliance with all Nasdaq continued listing requirements. This achievement was a result of our successful efforts to improve our balance sheet, including settlement agreements with vendors and successfully fundraising from private as well as institutional investors. Full compliance allows us, and eventually the combined company, continued access and exposure to the U.S. capital markets.

– Financial Restructuring: In addition, we have made important strides in eliminating all debt and strengthening our balance sheet. In October 2024, we closed a $3.2 million private placement and in December we announced a second private placement raising up to $1 million at a price of $3.10, representing a 15% premium to the market, subject to certain closing conditions including shareholder approval. The two private placements together (if closed), with our existing cash position, extends our runway to approximately 18 months. This new influx of capital also gives us flexibility to execute our strategy including the development of the DOXA compounds and complete the merger process smoothly.

Merger with Kadimastem Ltd.

In addition to solving our listing and financial challenges, we also announced a potential merger with Kadimastem, a company we believe offers compelling strategic benefits, not only for the combined company but also for our shareholders. Kadimastem’s expertise in the development of innovative cell-based therapies will allow the DOXA program to thrive, and once the merger is finalized, these programs will become part of the merged company’s broader pipeline of neurodegenerative and diabetes candidates.

While Kadimastem will assume ownership of the active pipeline assets, including the DOXA program, NLS shareholders will retain an exclusive opportunity to benefit financially from the potential sale of our legacy assets, including Mazindol, through the contingent value rights (CVR) agreement associated with the merger.

Mazindol, which has long been part of our portfolio, is a key asset that received significant attention from private companies and therefore we believe holds significant potential for future value generation post-merger. We remain committed to maximizing this opportunity.

Looking Ahead: A Focused Strategy on Value Creation

The recent months have been a time of great challenge and achievement for NLS. As the merger is expected to close by the end of January 2025 and the integration process begins, we remain grateful for your continued support. We are committed to maximizing shareholder value through the potential sale of our legacy assets in the CVR and the combined company’s strengthened neurodegenerative and diabetes focused advanced clinical pipeline. With this strategy in place, we look forward to a future that is focused on value creation and the success of the DOXA program under Kadimastem’s leadership.

Thank you for your ongoing support as we move forward with this exciting next chapter.

Sincerely,

Alex Zwyer, CEO

About NLS Pharmaceutics Ltd.

‍

PIPELINE

Lead Asset: Mazindol ER

Mazindol ER is a patented and proprietary formulation of the active compound mazindol, and are designed for once-daily dosing. Mazindol has a well-established safety record from its long history of clinical use in the United States and in Europe when the drug was approved in an immediate release formulation for the management of obesity. Mazindol was marketed for nearly 30 years under the trade name Sanorex® before being voluntarily withdrawn from the market, and the drug is no longer available nor marketed in these regions. During its time on the market, mazindol was also widely used off-label and prescribed under compassionate use for the treatment of narcolepsy for several decades. Use in these compassionate use programs has yielded evidence of positive efficacy in patents suffering from the symptoms of narcolepsy including patients that were refractory to approved treatments for the disorder. Additionally, these same programs, a retrospective analysis of investigator sponsored studies, and NLS’s own trial evaluating Mazindol ER in patients with ADHD provide evidence of the drug’s favorable safety profile at doses that yielded efficacy signals.

We believe that our lead product candidate,  Mazindol ER, offers a differentiated profile with clincally meaningful advantages over current treatment options for narcolepsy for the following reasons:

Mechanism of action

If approved, Mazindol ER would be the only partial orexin 2 receptor agonist as well as the only triple monoamine reuptake inhibitor approved by the FDA for the treatment of narcolepsy. Narcolepsy is caused by a profound loss of orexin producing neurons. A partial orexin 2 receptor agonist may help to replace missing endogenous orexin peptide, addressing the underlying cause of the disease. In addition, the drug’s action as a triple monoamine reuptake inhibitor can further reduce disease specific symptoms, offering patients a treatment option that may address the two primary symptoms of narcolepsy – excessive daytime sleepiness (EDS) and cataplexy attacks – in a convenient once-daily oral tablet.

Low potential for abuse, misuse, and diversion.

Mazindol is currently classified by the DEA as a Schedule IV controlled substance . The DEA defines Schedule IV controlled substances as those “with a low potential for abuse and a low risk of dependence”. Unlike Xyrem® (sodium oxybate), the top-selling treatment for narcolepsy in the United States deemed to have a high potential for abuse/misuse (Schedule III), mazindol was never required by the FDA to have a risk evaluation and mitigation strategy (REMS) program in place to manage known or potential serious risks associated with its use.

Quilience® has potential to be administered as a monotherapy.

Narcolepsy is a difficult disorder to manage and even with available treatments, the majority of narcolepsy patients often require multiple medications to treat their symptoms. According to the current treatment guidelines (initially published in 2007) of the American Academy of Sleep Medicine, or AASM, medications for narcolepsy, at best, provide only moderate improvement in narcolepsy symptoms, and their respective side effects may limit their use. The AASM specifically highlights that future investigations should be directed toward more effective and better tolerated therapies for treatment. The Voice of the Patient report from the FDA’s patient-focused drug development initiative, published in 2014, concluded that, based on the overall benefit-risk assessment of current medications, there is a continued need for additional effective and tolerable treatment options for patients with narcolepsy. A retrospective analysis (Nittur et.al, Sleep Med. 2013 Jan;14(1):30-6) showed that mazindol has a long-term, favorable benefit/risk ratio in 60% of drug-resistant patients with hypersomnia, including a clear benefit on the two primary symptoms of narcolepsy–EDS and cataplexy.

Mazindol ER is being developed as a once-daily oral tablet administered in the morning upon wakening.

Patients have identified a need for treatment options that are easier to take, dosed less frequently, do not disrupt nighttime sleeping, and provide full day coverage of symptoms. We believe that once-daily dosing with Mazindol ER may address this need and may help improve patient compliance and adherence with treatment. Mazindol ER utilizes our patented and proprietary extended-release (ER) formulation and is being designed to optimize its pharmacokinetic and pharmacodynamic properties with a rapid onset of action and prolonged controlled therapeutic effect, allowing for a daily oral dose that effectively provides consistent and long-acting symptom control to uniquely meet the needs of patients.

Relationship Between Narcolepsy and ADHD

Narcolepsy and psychiatric disorders have a significant but under-recognized relationship in which the two may coexist. However, narcolepsy is frequently misdiagnosed initially as a psychiatric condition, contributing to protracted times for accurate diagnosis and treatment. Narcolepsy is a disabling neurological condition that carries a high risk for the development of social and occupational dysfunction. Deterioration in function associated with narcolepsy may lead to the secondary development of psychiatric symptoms and inversely, the development of psychiatric symptoms can lead to a deterioration in function and quality of life. The overlap in treatments may further enhance the difficulty to distinguish between diagnoses.

ADHD is the most common neurobehavioral disorder characterized by symptoms of inattention, impulsivity and hyperactivity with an estimated prevalence rate of approximately 4-12% worldwide, as reported by the paper, “Understanding Attention Deficit/Hyperactivity Disorder From Childhood to Adulthood,” by Drs. Timothy E. Wilens and Thomas J. Spencer.

On the surface, ADHD may appear to be the opposite of narcolepsy; however, there may actually be significant clinical similarities between the two disorders. Cumulative data on sleep problems in children and adolescents with ADHD have shown that children with ADHD have had a higher rate of restless sleep, impaired sleep, and daytime sleepiness than children without ADHD. However, it is unclear whether EDS in ADHD is due to nocturnal sleep disturbances or primary vigilance disorders because shorter sleep onset latency is assessed in ADHD patients by the Multiple Sleep Latency Test, rather than in the control group irrespective of the presence/absence of sleep disturbances.

Alternatively, problems with sleep may represent an intrinsic component of ADHD. The presence of ADHD symptoms in children and adolescents with narcolepsy has been found to be about two-fold higher than in the general control population. Adults with narcolepsy have been found to have a much greater likelihood of having a diagnosis of ADHD in childhood compared to the general control population. Hyperactivity seen in ADHD may, in fact, be a compensatory response for individuals who are under-aroused or sleepy, and ADHD symptoms contribute to poor quality of life and increased frequency of depressive symptoms, similar to narcolepsy. To the best of our knowledge, almost all of the treatments used in ADHD have mechanistic overlap with treatments used in narcolepsy for EDS, and researchers suggest that the symptoms of EDS, fatigue, and sleep fragmentation may be the cause for ADHD symptoms, which is consistent with similar findings in other hypersomnia disorders.

AstroRx, the medical product for ALS treatment that is being researched by Kadimastem, the company NLSP has signed a binding merger agreement with, was granted Orphan drug status by the FDA. This status grants the company that manufactures the drug marketing exclusivity for 7 years from the date of receipt of marketing approval of the drug. The recognition of orphan drug status also enables accelerated examination and response paths from the FDA and other regulatory authorities.
‍

Additionally, Kadimastem is focused on the generation and manufacturing of pancreatic insulin secreting islets (IsletRx) from embryonic stem cells for the treatment of insulin dependent diabetes such as Type 1 Diabetes. This program is in pre-clinical phase and they are moving fast down the regulatory path to start human trials. The number of patients with diabetes was estimated to be over 366 million worldwide in 2011 and is projected to be more than 552 million in 2030.  The American Diabetes Association (ADA) estimated the total annual costs of diabetes to be US$223.5 billion (in the US alone). The global cost is estimated to be US$465 billion annually and will grow to about US$510 billion by 2030.

‍

https://822bd25cb58ea4c4282ffd3ae03a082c.safeframe.googlesyndication.com/safeframe/1-0-40/html/container.html

MANAGEMENT TEAM

AlexZwyer, MBA

Chief Executive Officer & Co-Founder

Alex Zwyer

A co-founder of the company with extensive operational, C-level pharmaceutical experience as well as a serial entrepreneur and strong leader with a proven track-record.

Alex Zwyer has served as our Chief Executive Officer and as a Director since our incorporation in August 2015. Mr. Zwyer has over 25 years of international business experience of which more than 10 years as a C-level executive in the pharma/biotech field. In 2007, prior to, and until founding NLS in 2015, Mr. Zwyer founded a startup in the high-end luxury food sector, and served as its chief executive officer until 2015 when he successfully sold the company. From 1991 and until 2007, Mr. Zwyer served in various positions with Viforpharma AG (SWX: VIFN) (then known as Vifor (International) Inc.), most notably serving as Executive Vice President (chief operating officer), leading the company’s global regulatory affairs, medical affairs, sales and marketing as well as business development teams. Mr. Zwyer speaks seven languages fluently. Mr. Zwyer holds a B.B.A. in business administration from Oekral, Zurich, Switzerland and an executive M.B.A. from GSBA/Lorange Institute of Business, Zurich, Switzerland and an M.B.A. from University at Albany SUNY.

‍

‍

GeorgeApostol, MD MS

CMO & Global Head R&D

George Apostol

Dr. Apostol’s career spans more than 20 years in pharma industry and consists of a broad drug development expertise across early, middle and late phases of development at the global R&D organizations of Eli Lilly, Pfizer, Abbott, Novartis, Shire and Endo.

His main areas of capability include orphan diseases in CNS, in particular Fragile X Syndrome, Alagille Syndrome, but also ADHD, anxiety, depression, migraine, Parkinson’s and schizophrenia. He has built multiple drug development teams both in the US and Europe, several receiving distinguished corporate R&D awards and achieving multiple regulatory approvals in US, EU and Japan. He holds a MD degree from the Carol Davila Medical School in Romania and a MS in Clinical Research from University of Minnesota.

‍

‍

‍

‍

EricKonofal, MD, PhD

Chief Scientific Officer and Co-Founder

Eric Konofal

A co-founder of the company with a deep knowledge and experience in clinical and scientific research. He is also a drug-hunter & pipeline developer for sleep disorders as ADHD.

Dr. Konofal is a primary clinical and international scientific researcher, and is an accomplished drug hunter and drug pipeline developer. He is a senior medical consultant for the Pediatric Sleep Disorders Center at Robert-Debre University of Paris (APHP). Dr. Konofal served as Principal Clinical Investigator at the Clinical Pharmacology & Pharmacogenetic Department at Robert-Debre University of Paris. His research has focused on brain- and iron-dopamine interactions in subjects with neurological sleep disorders (RLS, PLMS), and ADHD. Additionally, Dr. Konofal served as a consultant at the sleep disorder center of Pitié-Salpêtrière University Hospital Group (APHP), specializing in ADHD, RLS, PLMS and CDH. He initiated previous studies based on iron and its role in the pathophysiology of ADHD, and has conducted extensive research on the relationship between the brain and iron.

He launched a clinical trial on the efficacy of mazindol in children with ADHD (clinicaltrials.gov identifier: NCT00508677) and obtained the U.S. patent for mazindol in the treatment of ADHD. Dr. Konofal wrote the scientific rationale for Nolazol® and discovered the pharmacological profile of mazindol and its orexin-2 receptor binding properties. He has authored over 70 peer-reviewed publications in the area of sleep disorders and other CNS diseases.

‍

ElenaThyen-Pighin

Chief Financial Officer

‍

Elena Thyen-Pighin

‍

Ms. Thyen-Pighin holds extensive experience in leadership and management functions as both head of finance and human resources across a number of industries. Based in Switzerland, Ms. Thyen-Pighin has a successful track record, most notably in accounting for both private and publicly listed enterprises.

‍

‍

‍

‍

‍

‍

‍

‍

‍

NEWS

NLS Pharmaceutics CEO Issues Letter to ShareholdersDec 11, 2024NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the MarketDec 4, 2024NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological DisordersDec 3, 2024NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological DisordersNov 18, 2024NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger AgreementNov 4, 2024NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing RequirementsOct 28, 2024NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin DependenceOct 21, 2024NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing RulesOct 15, 2024NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share SplitSep 25, 2024NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to MergeJul 29, 2024

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND USD BY LFG EQUITIES CORP FOR A ONE DAY NLSP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

BNZI

CHECK OUT THE INVESTOR PRESENTATION HERE

________________________

Hello Everyone,

This past two months have been amazing here at MicroCapAlerts.io.  We have had the great privilege of being able to profile several companies that have made double and triple digit moves in the days and weeks following our email alerts. The last few have seen some heavy action and we had one last week mount a major comeback after dipping down to .65 and launching back to .90 over the next few sessions.

We have a new bounce profile for you to research for Wednesdays session.

Pull up BNZI immediately.

Banzai is a marketing technology company that provides essential marketing and sales solutions for businesses of all sizes. On a mission to help their customers achieve their mission, Banzai enables companies of all sizes to target, engage, and measure both new and existing customers more effectively. Banzai customers include Square, Hewlett Packard Enterprise, Thermo Fisher Scientific, Thinkific, Doodle and ActiveCampaign, among thousands of others.‍

CATALYSTS

The LARGEST platform for finding software and services. More than 100 million people visit Capterra, GetApp, Software Advice, and UpCity across over 70 localized sites every year to read objective research and verified customer reviews that help them confidently choose the right software and services. Thousands of B2B companies work with Gartner Digital Markets to build their brand, capture buyer demand, and grow their business.

Banzai is a SaaS company building an AI-driven platform of essential MarTech data, analytics, and data-driven applications.Banzai is fueling marketing results with cutting-edge AI solutions.

SaaS company building an AI-driven platform of essential MarTech data,analytics, and data-driven applications

• While the global MarTech market is accelerating, marketers are struggling with an explosion of vendor complexity

• Banzai is fueling marketing results with an integrated platform of AI-PoweredMarTech solutions

• Reach deploys multi-channel outbound campaigns and is becoming the marketing automation AI demand gen platform standout• Demio provides transparent webinar insights for data-driven marketers with upstream updates launching in Q4

• Additional upside in strategic acquisitions with a substantial gap between current private vs. at-scale public market valuations

Banzai Announces Definitive Agreement to Acquire OpenReel, Growing TTM Revenue 152% to $10.9M

Banzai Adds Enterprise-Grade Branded Video Creation and Management Solution OpenReel to Growing Product Family

BNZI has signed a definitive agreement to acquire OpenReel, a leading digital video creation platform.

OpenReel enables companies to rapidly create high-quality, branded video content. Their solution allows companies to direct, record, create, and collaborate on high-definition video projects, dramatically reducing the time to create brand-compliant video content. OpenReel’s enterprise customer base includes global organizations, such as Bristol Myers Squibb, Ingram Micro, DXC Technology, Insider Inc., and US Steel.

“Video is the future of enterprise marketing,” said Joe Davy, Founder and CEO of Banzai. “OpenReel gives their customers a 10x advantage when creating branded video content. Their enterprise customers are a testament to the power of their solution.”

“We’re thrilled to join the Banzai family and take OpenReel to new heights,” said Lee Firestone, CEO and co-founder of OpenReel. “With Banzai’s support, we’re confident in accelerating the growth of our technology while becoming an integral part of their robust suite of marketing tools. We believe that OpenReel is the perfect complement to Demio, enabling seamless cross-collaboration and enhancing the value we deliver to marketers worldwide.”

OpenReel is a leading enterprise video creation and management solution that empowers companies to create high-quality content at scale and on brand. OpenReel enables businesses of all sizes to cut down on the time-and resource-intensive process of video creation and scale content creation initiatives efficiently, effectively, and securely. OpenReel is trusted by a wide range of customers from small businesses to the Fortune 500. OpenReel is based in New York, with its team distributed worldwide.

BNZI’s vision is to build an AI-powered marketing technology platform to help businesses of all sizes grow.

Banzai Announces Expanded Partnership with Salesforce, Today’s Industry Leading AI CRM Company for Smarter Webinar Campaigns

Simplified Workflows and Real-Time Insights with Account Engagement Integration in Demio Give Salesforce Users the Tools They Need to Enhance Their Webinar Strategy

SEATTLE, Oct. 17, 2024 (GLOBE NEWSWIRE) — Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and sales solutions, today announced significant enhancements to its Demio platform through deeper integration with Salesforce, the industry leading AI CRM company.

These new features address key operational challenges faced by marketing teams, delivering an improved level of precision in webinar data management, from automated lead capture to real-time UTM tracking. Marketers leveraging this integration will not only see immediate efficiency gains but will also benefit from enhanced decision-making capabilities, thanks to cleaner, more accurate data pipelines.

Key Enhancements Designed to Maximize Efficiency and Insight

This integration addresses common pain points for Salesforce Account Engagement users by automating the syncing of webinar data—from contact information to UTM tracking—greatly reducing the time and effort required for manual processes. Marketers can now focus on optimizing campaigns with real-time insights, enabling data-driven adjustments with speed and precision. The seamless UTM tracking integration offers a comprehensive view of campaign performance across channels, while Demio’s smart list management feature ensures that webinar registrants are automatically added to targeted Salesforce Account Engagement lists, ensuring no lead slips through the cracks.

Key capabilities include:

  • Automated List Management: Simplify the process by automatically syncing registrants to Salesforce Account Engagement, ensuring optimal engagement across the funnel.
  • Real-Time UTM Tracking: Gain holistic insights into campaign performance with real-time tracking at both session and individual contact levels.
  • Advanced Search for List Management: Quickly navigate extensive lists with Demio’s new auto-search feature, saving time and boosting productivity.
  • Custom Field Syncing: Ensure accurate and up-to-date information across platforms, enabling targeted segmentation and precision marketing.

Joe Davy, CEO of Banzai, emphasized the power of this upgraded integration: “By deepening our connectivity with Pardot, we’re offering marketers a more scalable, data-rich experience. This isn’t just a product enhancement; it’s a strategy shift that will drive better outcomes with less effort.”

A Future-Focused Solution for Salesforce Customers

Banzai continues to innovate to ensure its solutions meet the evolving needs of marketing teams. By integrating powerful features directly into users’ workflows, this enhancement sets a new standard for what’s possible in webinar campaign management—paving the way for more strategic, data-driven marketing operations.

About Salesforce

Salesforce is the #1 AI CRM, empowering companies to connect with their customers in a whole new way through the power of CRM + AI + Data + Trust on one unified platform: Einstein 1. For more information visit: www.salesforce.com.

NEWS

Banzai Announces Definitive Agreement to Acquire OpenReel, Growing TTM Revenue 152% to $10.9MDec 10, 2024Banzai to Participate in the iAccess Alpha Virtual Best Ideas Winter Conference on December 10-11, 2024Dec 6, 2024iAccess Alpha’s Buyside Best Ideas Virtual Winter Conference December 10-11, 2024Dec 6, 2024New to the Street Engages Curate by Banzai to Elevate Investor and Brand EngagementDec 4, 2024Banzai Engages ShareIntel to Investigate Potentially Improper and Illegal Trading Activity in the Company’s Common StockDec 4, 2024Banzai Board of Directors Approves Purchase of Bitcoin as Treasury Reserve AssetNov 26, 2024Banzai’s Demio Wins Multiple Recognitions from Gartner Digital Markets in 2024Nov 19, 2024Banzai Reports Third Quarter 2024 Financial Results; Annualized Adjusted Net Loss Improvement of $12.2 MillionNov 14, 2024Banzai Regains Compliance with Nasdaq Minimum Market Value of Publicly Held Shares RequirementNov 11, 2024Banzai Q3 2024 Preliminary Financial Results: Profitability in Sight Following $14.5M Annualized Adjusted Net Income Improvement; 31% Annualized ARR Growth RateNov 7, 2024

MANAGEMENT

‍

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY SIDEWAYS FREQUENCY LLC FOR A ONE DAY BNZI AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

VZLA

‍

CHECK OUT THE WEBINAR HERE

CHECK OUT THE INVESTOR PRESENTATION HERE

_________________________

Hello Everyone,

Our last profile certainly reacted strange. It was down on Thursday the day we did it. It closed at .65, the low of the day. It saw record interest on the session. Friday we saw this one mount a major comeback and close up 25% after running all the way to .87. The previous days highs were .95 during the session but it was up over 1.10 in the premarket. Congrats on that one! We are going to keep an eye on it early this week.

We have a brand new profile for you to talk a look at for Mondays session.

Pull up VZLA right away.

The outlook for silver and silver stocks is generally positive, particularly over the medium to long term. The combination of industrial demand (particularly in renewable energy and technology), potential supply challenges, and macroeconomic factors such as inflation or geopolitical instability suggest that silver should maintain and even increase its value.

Vizsla Silver is a Canadian mineral exploration and development company headquartered in Vancouver, BC, focused on advancing its flagship, 100%-owned Panuco silver-gold project located in Sinaloa, Mexico. To date, Vizsla Silver has completed over 380,000 metres of drilling at Panuco leading to the discovery of several new high-grade veins. For 2024, Vizsla Silver has budgeted +45,000 metres of resource/discovery-based drilling designed to upgrade and expand the mineral resource, as well as test other high priority targets across the district.

Silver’s use in solar panels, batteries, and electronics could see further growth, especially with the increasing demand for electric vehicles (EVs) and solar power. The push for decarbonization worldwide is likely to keep silver in demand for these applications.

Investment Highlights

  • Vizsla Silver is developing the Panuco Silver-Gold Project in Mexico, aiming for first silver production in 2027 – only two years from now!
  • Recent PEA shows US$1.1B NPV (5%) with 86% IRR and 9-month payback – and this is based on conservative metal prices!some text
    • Net Present Value (NPV) is used to help measure the value of a mining project. It is a vital financial metric in the mining industry, serving as a barometer for the profitability and viability of a mining project.
    • Considering that VZLA’s market cap is only around U$480M (as of 11/12), the company has ample room to catch up to this NPV!
  • Resource of 325M oz silver equivalent – (payable Silver Equivalent (AgEq.) calculated by dividing gross sales revenue by $26.00 silver priced) – and only 9% of known vein strike has been explored so far!
  • The Panuco Project is positioned to become one of world’s largest primary silver producers at 15M oz/year – +20M oz in early years!
  • The company is well-funded with US$90M+ cash – the company is targeting a feasibility study in summer 2025! The company intends to make a production decision only following release of a positive feasibility study.
  • Vizsla Silver holds a steadfast dedication to environmental, social, and governance (“ESG”) excellence in all its endeavors. The company’s goal is to operate as a transparent and financially viable company dedicated to conscientious mining while continuously advancing in social, environmental, and technological innovation.
  • Recent approval to graduate from the TSX Venture Exchange to the Toronto Stock Exchange (“TSX”). Uplisting to the TSX represents another significant growth milestone for shareholders as the TSX is Canada’s premier stock exchange. This is likely to increase market visibility and provide exposure to a broader range of investors!
  • A methodical approach to development suggests a clear focus on maintaining momentum while managing execution risk.

Panuco Project

District Scale & 100% Owned

  • Applying modern exploration techniques to a newly consolidated land package that has never been systematically explored
  • Tripled land package since January 2024, now over 17k ha

Location, Location, Location

  • Situated in an underexplored area of the emerging Western Mexico Silver Belt
  • 80km from San Dimas (1Bn+ Oz AgEq in production(1) + reserves)

Existing Infrastructure

  • Past producing district that benefits from access to HV power, water, roads, and proximal to Mazatlán
  • To date, Vizsla has completed over 375,000 metres of diamond drilling without constructing a single road

World’s Largest Undeveloped High-Grade Silver Primary Resource Advancing to Production

  • Upgrading resources to higher confidence categories
  • Test mine planned for Q4 2024 to de-risk initial production
  • Targeting first silver in H2 2027

Corporate Strength

  • Vizsla is well funded with $100M+ in cash plus ITM options(2) & warrants, no debt, and industry leading team & board
Panuco Overview Map 1

‍

NEWS

VIZSLA SILVER COMMENCES TEST MINING AND BULK SAMPLE PROGRAM AND PROVIDES EXPLORATION UPDATE AT PANUCO PROJECT3 days agoVIZSLA SILVER RECEIVES FINAL APPROVAL TO GRADUATE TO THE TORONTO STOCK EXCHANGENov 5, 2024VIZSLA SILVER RECEIVES CONDITIONAL APPROVAL TO GRADUATE TO THE TORONTO STOCK EXCHANGE AND ANNOUNCES CORPORATE UPDATENov 1, 2024VIZSLA SILVER RECIEVES NATIONAL RECOGNITION FOR ITS HEALTH, SAFETY AND SUSTAINABILITY EFFORTS FOR THIRD YEAR IN A ROWOct 29, 2024VIZSLA SILVER COMPLETES ACQUISITION OF LA GARRA-METATES DISTRICTOct 17, 2024VIZSLA SILVER ANNOUNCES $65 MILLION BOUGHT DEAL FINANCINGSep 16, 2024VIZSLA SILVER UPDATES AT-THE-MARKET EQUITY PROGRAMSep 13, 2024Vizsla Royalties Announces Resumption of Trading in WarrantsAug 30, 2024VIZSLA SILVER FILES PEA TECHNICAL REPORT ON THE PANUCO PROJECTAug 28, 2024Vizsla Royalties Announces Halt of Trading in WarrantsAug 28, 2024VIZSLA SILVER CONFIRMS EXCEPTIONAL CONTINUITY OF HIGH-GRADE SILVER AND GOLD THROUGH ONGOING INFILL DRILLING AT COPALA CENTRALAug 28, 2024Vizsla Royalties to Commence Trading on TSX Venture on August 26, 2024Aug 22, 2024VIZSLA SILVER PROVIDES EXPLORATION UPDATE ON PANUCO PROJECT: OUTLINES 10KM DRILL PROGRAM TO TEST NEW TARGETS IN THE EAST AREAAug 21, 2024Vizsla Royalties Announces Share ConsolidationAug 2, 2024Vizsla Royalties Closes Private Placement Raising Gross Proceeds of $5.2MAug 1, 2024Vizsla Royalties Closes First Tranche of Private Placement Raising Gross Proceeds of $5MJul 29, 2024VIZSLA SILVER DELIVERS EXCEPTIONAL ECONOMICS FOR PANUCO IN PRELIMINARY ECONOMIC ASSESSMENTJul 24, 2024Vizsla Royalties Announces Shares for Debt TransactionJul 18, 2024Vizsla Royalties Announces $3.7 Million Private PlacementJun 27, 2024VIZSLA SILVER HITS VISIBLE GOLD IN HIGHEST GRADE INTERCEPT EVER AT PANUCO: 9,920 G/T SILVER & 663 G/T GOLD OVER 0.64 METRES TRUE WIDTH AT COPALAJun 26, 2024

‍

MANAGEMENT

Michael A. Konnert

President, Chief Executive Officer

Mike K Vzla.200x200

Michael Konnert is a mining entrepreneur with deep expertise in deal-making, financing, team leadership and strategic corporate development. As the Founder, President, Director and CEO of Vizsla Silver Corp. (NYSE:VZLA), he has successfully led the company in consolidating one of Mexico’s highest-grade silver and gold districts, positioning it to develop one of the world’s largest single-asset silver producers. He is also co-founder and Managing Partner of Inventa Capital, a natural resource incubator company dedicated to acquiring and developing assets in the natural resource sector. Since its founding in 2017, Inventa has raised over C$800M in capital, focusing on discovering emerging opportunities in the industry.

In 2017, Michael co-founded CobaltOne Energy Corp, a battery metal exploration company, which he successfully led to acquisition by Blackstone Minerals (ASX: BSX). He also serves as Executive Chairman of Vizsla Royalties and holds board positions at Vizsla Copper (TSX-V: VCU) and Summa Silver (CSE: SSVR). Michael’s career is marked by his strategic vision, commitment to sustainable development, and innovative approach to the mining industry.

‍

Mahesh Liyanage

Chief Financial Officer

20240925 2024 Lz Office Hs 3934

Mr. Liyanage is a seasoned, organized, and responsible Chartered Professional Accountant with more than 20 years of experience across diverse industries. Special strengths in Canadian public company reporting and regulatory compliance, business spin-offs/mergers and acquisitions, treasury management, Canadian and US tax compliance. He has many years of experience with Mexican mining companies and specializes in helping Canadian companies achieve optimal operations in Mexico. He was most recently with Evrim/Orogen and in the past he had worked with the Manex Resource Group.

‍

‍

‍

‍

‍

‍

‍

‍

Simon Cmrlec

Chief Operating Officer & Director

Simon Cmrlec 200x200.200x200

Mr. Cmrlec is a highly experienced senior engineer with over 30-years of industry experience who has been a director of Vizsla Silver since its formation and has most recently held the position of Chief Operating Officer of Ausenco, a global mining engineering and consulting firm. He has extensive experience in building mining projects around the world and across a number of different commodities and will be tasked with advancing Vizsla Silver’s world-class Panuco silver-gold Project towards production, with the goal of becoming one of the world’s largest single-asset silver producers.

Mr. Cmrlec began his career with Western Mining Corporation (WMC) at its Olympic Dam Mine in South Australia where he held several technical and operations roles. He was an Owners Representatives for the Olympic Dam Expansion Project (ODP) where he supported the design, construction and commissioning of the Smelter and Hydrometallurgical facilities. Following the completion of the ODP project Mr. Cmrlec joined Kvaerner and was involved in the construction and commissioning of various base metals, iron ore and gold projects in the US, South America, Middle East and South Africa. In 2001, he joined Inco on the Goro Nickel project in New Caledonia as the Project Manager responsible for the Refinery facility. Mr. Cmrlec held a number of roles on the Goro Nickel project including Senior Project Manager and Construction director in his eight years there. Mr. Cmrlec joined Ausenco in 2009 as the Manager, Project Delivery before assuming the role of President APAC/Africa. In 2015, Mr. Cmrlec moved to Canada and became Ausenco’s President North America before transitioning to President Americas in 2017 and the Chief Operating Officer in 2019.

Simon attended the Gartrell School of Mining, Metallurgy and Applied Geology at the University of South Australia and graduated with a B.Eng (Hons) in Metallurgical Engineering in 1994.

Michael Pettingell

SVP, Business Development and Strategy

Mp Headshot 2024

Mr. Pettingell is a geologist with over 10 years of experience working in both pre-producing and operating mines, as well as the capital markets. Prior to joining Vizsla, Michael spent the last four years working in equity research at Canaccord Genuity covering junior precious and base metal explorers and developers in the mining and metals sector. Prior to Canaccord, Mr. Pettingell worked for Hecla Mining, first in exploration at its Lucky Friday unit, and then in corporate development located in Vancouver. Michael started his career as an exploration geologist for Romarco Minerals at its Haile Gold mine prior to it being acquired by OceanaGold in 2015. Michael holds a Bachelor of Science in both Geology and Economics from the University of South Carolina and a Master of Applied Science in Mining Engineering from the University of British Columbia.

‍

‍

‍

‍

‍

Jesus Velador

VP, Exploration

Jesus Velador.200x200

Dr. Velador has more than 20 years of experience in precious metals exploration, specializing in epithermal systems. Recently, he worked with Fortuna Silver Mines Inc., where he managed brownfields exploration programs in Mexico and Peru. Dr. Velador previously served as Director of Exploration for First Majestic Silver Corp., where he managed the exploration team that discovered the silver and gold deposit at Ermitaño, located adjacent to the company’s Santa Elena mine in Sonora, Mexico. Dr. Velador started his career working for Industrias Peñoles where his work was instrumental in the discovery of the Valdecañas Vein at the Juanicipio project, a Fresnillo – MAG Silver joint venture. Jesus earned a B.Sc. from the University of Chihuahua, a M.Sc from the University of Texas at El Paso and a Ph.D (Epithermal deposits) from the New Mexico Institute of Mining and Technology.

‍

‍

‍

‍

Hernando Rueda

Director of Mexico

Hernando Rueda Headshot.200x200

Mr Rueda is a Professional Geologist with 20+ years of experience.

Former Regional Exploration Manager at Capstone Mining and former Project Evaluation Manager with Agnico Eagle.

‍

‍

‍

‍

‍

‍

‍

Jennifer Hanson

Vizsla Silver Jen Hanson

Jennifer is a dedicated and versatile Senior Professional that brings more than 22 years of excellence in all aspects of human resource management, accounting, and administration, by generating invoices, resolving problems quickly, designing email system, processing income statement requests, administering HR functions, and achieving outcomes through a people-first method.

‍

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVEN THOUSAND FIVE HUNDRED USD BY SIDEWAYS FREQUENCY LLC FOR A ONE DAY VZLA AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

AYRO

CHECK OUT THE INVESTOR PRESENTATION HERE

‍________________________

Hello Everyone,

We have a brand new profile that trades on the Nasdaq and is sitting well under a buck right now.

This company operates in one of the hottest sectors of the past 5-10 years and is bridging the gap in a major market with their niche vehicles that fill a void in the sector that has yet to be addressed.

Pull up AYRO immediately.

You are going to want to keep this one on your radar for the rest of the week.

AYRO designs and produces zero emission vehicles and systems that redefine the very nature of sustainability. Their goal is to craft solutions in a way that leaves minimal impact on not only carbon emissions, but the space itself. From tire tread, fuel cells, sound, and even discordant visuals, we apply engineering and artistry to every element of our product mix. The AYRO Vanish is the first in this new product roadmap. At AYRO, they strive to clarify true sustainability. They are not just about limiting our footprint, but removing our footprint all together – creating limited disruption.

The LSEV (Low-Speed Electric Vehicle) sector refers to a growing market of electric vehicles designed for short-distance travel, typically limited to a top speed of 25 to 35 mph (40 to 56 km/h). These vehicles are popular for use in urban environments, gated communities, resorts, and campuses, where their small size, energy efficiency, and lower cost make them ideal alternatives to conventional cars. LSEVs are typically powered by small battery packs and can be charged via standard outlets, making them accessible for everyday use. As cities become more congested and demand for sustainable transportation grows, the LSEV sector is experiencing expansion, driven by technological advancements, increasing environmental awareness, and government incentives. This niche sector is expected to continue to evolve as part of the broader shift toward electric mobility, with innovations in design, battery technology, and connectivity features.

The AYRO Vanish

The AYRO Vanish is purpose-built, innovative, and highly customizable to meet any need in last-mile delivery, micro distribution, and campus / facility mobility needs.

The lightweight architecture of the AYRO Vanish is designed to limit vehicle weight and maximize payload capacity. The vehicle offers highly adaptable bed configurations to support both light- and heavy-duty needs in a variety of applications.The Vanish is a purpose-built, innovative, and highly customizable LSEV unlike any other on the market to support campus mobility, last-mile delivery and micro distribution needs.

‍

The AYRO Valet (Coming Soon)

AYRO Partners with GLV Ventures for Lower Cost Engineering and Manufacturing Based in the United States

PUBLISHED

DEC 4, 2024 9:15AM EST

Beginning with the Company’s Vanish electric vehicle, AYRO will utilize GLV’s lower cost U.S.manufacturing footprint to add new partnerships and secure new purchase orders

ROUND ROCK, TX / ACCESSWIRE / December 4, 2024 / AYRO, Inc. (NASDAQ:AYRO) (“AYRO” or the “Company”), a designer and manufacturer of electric, purpose-built delivery vehicles and solutions for micro-distribution, micro-mobility, and last-mile delivery, today announced a partnership with GLV Ventures for the engineering and manufacturing of the Company’s electric vehicle, the Vanish. The relationship will launch with the re-engineering and manufacturing of the Vanish in the United States using its original specifications.

Josh Silverman, AYRO’s Executive Chairman, commented, “We are partnering with GLV to redesign the Vanish vehicle to produce a more viable vehicle using lower-cost production and engineering methods, while also ensuring that the vehicle is made in America at GLV’s Beeville, Texas manufacturing facility. We believe that there is a significant market for low-speed EVs, like the Vanish, and we are dedicated to prudent and careful application of capital and resources to optimize its manufacture and distribution, all while ensuring that these vehicles are made in America. While GLV’s low-cost manufacturing should help enable us to redesign the Vanish, improve unit profitability and enhance competitiveness in the global market, our principal objective is to leverage this relationship to secure additional partnerships and drive new orders. We look forward to providing progress updates on this and future projects.”

GLV Ventures has been producing high-quality niche product tooling and production vehicle assemblies since its founding in 1996. GLV has full homologation and certification capabilities from inception to completion. Its capabilities include chassis manufacturing, vacuum thermoforming, carbon fiber and open molding infusion products for exterior body panels on specialty vehicles and other niche product applications. Lower cost tooling, part design, readily available materials and faster tooling times are all value-added aspects of GLV’s offering, which provides the best technology from diversified industries. GLV boasts a successful vehicle department history, deep understanding of worldwide automotive certification and homologation processes, existing production facilities and processes, and established supplier relationships.

NEWS

AYRO Partners with GLV Ventures for Lower Cost Engineering and Manufacturing Based in the United States6 days agoAYRO Appoints New Management Team to Re-Engineer and Revamp a Lower Cost Low-Speed Electric VehicleAug 21, 2024AYRO Reports Year-End 2023 Financial Results and Provides Corporate UpdateApr 9, 2024

‍

AYRO Appoints New Management Team to Re-Engineer and Revamp a Lower Cost Low-Speed Electric Vehicle

Appoints new President of operating division and new CFO

ROUND ROCK, TX / ACCESSWIRE / August 21, 2024 / AYRO, Inc. (NASDAQ:AYRO) (“AYRO” or the “Company”), a designer and manufacturer of electric, purpose-built delivery vehicles and solutions for micro distribution, micro-mobility, and last-mile delivery, today announced that it has appointed Joseph Ramelli as AYRO’s new Chief Financial Officer and Gilbert Villarreal as President of AYRO’s operating subsidiary.

Joseph Ramelli has vast experience in various management roles, including chief executive officer, chief financial officer and president. Mr. Ramelli also has over 15 years of experience in varied roles at investment firms. AYRO believes that Mr. Ramelli’s management and capital markets experience will be instrumental in managing AYRO’s strong cash position and employing prudent financial rigor as AYRO continues to work towards bringing its innovative electrical vehicles to market, while also managing costs and maximizing profits.

Gilbert Villarreal is the founder of GLV Ventures, a leader in the design and production of a variety of vehicles including electric vehicles. GLV Ventures is known for its advanced manufacturing in a timely, cost-effective manner. Founded by Mr. Villarreal, GLV Ventures has operated in the manufacturing and design space for 25 years. GLV and its affiliate, EVESSA, are Tier 1 consulting and manufacturing companies that have produced electric vehicles and non-electric vehicles for several of the leading OEMs and Fortune 100 companies.

Josh Silverman, AYRO’s Executive Chairman, commented, “These high value additions to our management team are exactly what we need to move the Company forward. Gilbert, through his extensive experience in designing and developing electric vehicles in a cost-effective manner, will enable AYRO to offer Vanish at a significantly reduced cost. We believe this minimal lower risk investment in re-engineering our vehicles is an appropriate next step for AYRO. With a strong balance sheet, including $37 million in cash and cash equivalents as of the quarter ended June 30, 2024, we are well positioned to move the Company forward and maximize stockholder value. Redesigning the Vanish to be produced in a more cost-effective manner is the first step towards this goal. We also continue to evaluate other alternatives to maximize stockholder value, including M&A and/or capital investment opportunities.”

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIVE THOUSAND USD BY LFG EQUITIES CORP FOR A ONE DAY AYRO AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

KULR Profile

page24image1329751072

‍

*****KULR INVESTOR PRESENTATION*****

_________________________

Hello Everyone,

We have another profile back that you will definitely be familiar with.

KULR is no stranger to our list.

We brought you this one no less than a dozen times over the past few years.

There have been more than a few occasions in which we saw KULR take of in the days / weeks after we put it on your plate to research. It certainly does not lack volatility if that is what you are looking.

Let’s look at the last time we took a look at KULR for instance.

We brought you KULR on the 14th of November where it was trading below .40 that session.

By December 2nd it exploded all the way to 1.74 for a 350% move in just 2 weeks time.  

This was not the first time we have witnessed KULR pull off a crazy triple digit move that fast.

Check out the massive news they just dropped!

KULR Xero Vibe Solution Launches on NVIDIA Jetson Edge AI Platform

HOUSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a global leader in energy management and vibration reduction solutions, today announced the launch of its innovative KULR Xero Vibe™ (“KXV”) solution integrated with the NVIDIA Jetson edge AI platform. This new rollout combines superior vibration mitigation with artificial intelligence capabilities to enable high-performance, reliable operation in edge AI environments.

The NVIDIA Jetson platform, known for its powerful edge AI computing capabilities, offers unparalleled performance for edge applications such as robotics, autonomous machines, industrial IoT, and smart cities. KULR’s Xero Vibe™ solution complements the Jetson platform by addressing key operational challenges such as vibration suppression, ensuring optimal cooling system performance, reduced energy consumption, and extended mechanical lifespans.

KULR CEO Michael Mo highlighted, “The Jetson platform is NVIDIA’s Industrial AI-at-the-edge solution to connect the physical world to the Omniverse through AI agents for the Industrial Revolution 4.0. It’s the perfect platform for KULR to integrate our KXV technology and provide our customers a future proof AI-agent powered energy management edge device solution for data centers, renewable energy, electric mobility and industrial cooling applications. We are very excited to embark on this new era of AI-agent powered future with the NVIDIA platform.”

The edge AI market size is projected to grow from $24.05 billion in 2024 to $356.84 billion by 2035, representing a CAGR of 27.786% during the forecast period 2024-2035.

Key Features of the KULR Xero Vibe™ Solution:

  • Advanced Vibration Mitigation: KULR Xero Vibe™ utilizes proprietary vibration reduction technology to minimize mechanical stress, enhancing the reliability and longevity of AI edge devices.
  • Seamless AI Integration: While reducing vibration to virtually zero, KULR Xero Vibe™ is enhanced by NVIDIA Jetson platform’s real-time data processing and machine learning at the edge, unlocking new possibilities for AI-driven operations.
  • Durability in Harsh Environments: Designed for rugged and mission-critical use cases, the KXV solution supports operations in extreme conditions, making it ideal for industrial, aerospace, and defense applications.

Applications Across Industries:

The KULR Xero Vibe™ solution unlocks transformative opportunities across various sectors, including:

  • Data Centers: Enables data center fan cooling systems to run more efficiently and environmentally friendly which lowers operational and capex costs.
  • Wind-Powered Turbines: Diminished mechanical breakdown extends system lifespan leading to increased energy efficiency.
  • Bitcoin: Lowers energy consumption by generating less noise and reduced mechanical wear and tear in proof-of-work mining applications.
  • Robotics: Ensures seamless operation in precision robotics for industrial automation.
  • Aerospace, Defense, and Electric Aviation: Enables robust performance in mission-critical applications requiring ruggedized systems.

‍

CATALYSTS

  • Leveraging KULR’s roots in developing breakthrough cooling solutions for NASA space missions and backed by a strong intellectual property portfolio, KULR provides customers with industry-leading battery safety technologies as well as cost-effective cooling technologies that outperform traditional solutions.
  • KULR is currently processing up to 10,000 lithium-ion cells per week as well as preparing for tests performed by NASA, the Department of Defense (“DoD”), and others performing manned flighted missions.  
  • KULR was awarded three additional contracts with DoD prime contractors to implement the Company’s carbon fiber cathode solution for high-power magnetic and other covert pulse weaponry initiatives.  
  • KULR also secured a new battery safety contract with NASA to test its lithium-ion cells for future battery packs designed for the Artemis Program, a series of US-led international human spaceflight programs.  
  • KULR recently appointed former NASA Johnson Space Center senior leader Dr. William Walker as Director of Engineering.
  • KULR expects to procure lithium-ion battery cells providing up to 500-megawatt hours (“MWh”) of energy capacity, enough to power approximately 40,000 homes.
  • KULR just received a follow-on phase change material heat sink order from Lockheed Martin  
  • KULR has partnered with Lockheed Martin, Leidos and other prime contractors to develop and supply mission-critical technologies for hypersonic vehicles, high-power magnetic wave, and other defense systems.  
  • KULR’s portfolio of thermal management solutions target air and liquid-cooling of high-performance computing applications such as crypto mining, cloud computing, AI, and AR/VR simulations to maximize performance, energy efficiency and safety.

‍Energy Storage

The U.S. doubled its energy storage capacity in 2021 and is expected to increase 17x by 2030, according to Wood Mackenzie. Lithium-ion batteries are the dominant technology on the market for energy storage because of their cost and availability but do carry well documented safety risks. While rare, cell to cell thermal runaway in lithium-ion batteries can cause a fire or explosion.

‍For example, an explosion at Arizona Public Service’s McMicken battery plant injured four emergency responders in 2019 and overheating caused the 1.2 GWh Moss Landing storage facility in California to go off-line.‍

To reach net zero by mid-century will require an additional 245 GWh of battery capacity each year until 2030, but incidents of the like distill trust in battery technologies and threaten to slow the pace which is needed to achieve decarbonization goals. KULR’s passive propagation resistant (PPR) and thermal runaway shield (TRS) technologies prevent cell to cell thermal runaway propagation and inhibit fire and ejecta of a single cell from exiting the battery enclosure, making battery energy storage packs safe for homes, hospitals, schools, and universities, and more.‍

KULR is partnering with leaders in the energy storage industry such as Volta Energy Products, the subsidiary of Buffalo NY based parent company, Viridi Parente, to increase deployments of safe, reliable, and durable energy storage safety systems to accelerate the broader energy transition.

Battery Recycling and Management

KULR-Tech Safe_Case provides a safe and cost-effective solution to commercially store and transport lithium batteries, which is increasing in frequency as supply chain challenges and ESG commitments necessitate battery recycling and end-of-lifecycle management. Whether shipping a single battery, a battery-powered device or a load shipment of batteries, KULR’s technology mitigates the impacts of cell-to-cell thermal runaway propagation and ensures a safe journey. KULR’s Thermal Runaway Shield (TRS) technology is trusted by NASA to ship and store astronauts’ laptop batteries on the International Space Station. In addition, KULR combines its Passive Propagation Resistant (PPR) solutions with its new CellCheck intelligent battery management system to extend battery life. The CellCheck modular battery management system platform is KULR’s AI-powered battery safety technology for e-mobility, energy storage and fleet applications. It captures real time and lifetime battery intelligence, sensing adverse electrical, environmental, and physical events to analyze and control for maximum battery safety, reliability, and performance. As commercial industries across the board face greater scrutiny to comply with ESG standards, KULR is serving a total addressable market for a circular economic model for batteries that will reach over $21 billion by 2025 (estimated based on market data projections published by Grand View Research, Inc. stating that the global battery recycling market size is expected to reach $21.04 billion by 2025).

E-mobility

KULR is supporting the shift to electrified transport by enabling safer, lighter, and faster charging lithium-ion batteries for electric vehicles and micro mobility solutions.KULR’s passive propagation resistant (PPR) battery pack solutions increase battery energy capacity while preventing thermal runaway events that can lead to hazardous explosions, helping the transportation industry to address growing public safety concerns around electric vehicles, electric aviation and micro-mobility markets.

Vehicle technology advancements and EV range anxiety requires more battery capacity to expand the range and power of existing platforms while adding new, power-demanding components for advances such as 5G data networks. The additional strain on batteries increases the risk for overheating and serious failures and can damage sensitive chip architecture. In addition, overheating has been a key limiting factor for advancing fast charging battery technology. KULR’s carbon fiber thermal management technologies reduce the thermal resistance inside battery cells while increasing electrical conductivity to dissipate heat more efficiently to enable the safe deployment of fast charging batteries. With KULR, automotive OEMs and battery manufacturers can increase the energy capacity of battery cells so less cells are needed, making for lighter vehicles that drive further before needing to be charged.

Aerospace/Defense

KULR’s thermal management solutions enable the defense and aerospace industries to safely deploy electronic technologies that support critical missions and protect national security.Technology in this sector is developing at increasing rates – the space industry alone will be worth nearly $3 trillion in 30 years. The electronic devices being placed into aircrafts, satellites, and missiles are becoming ever smaller and more powerful. Lithium-ion batteries, which are already prone to overheating and propagation, are exposed to harsh thermal environments as well as shock and vibration during aerospace and defense operations. KULR has partnered with Lockheed Martin, Leidos and other prime contractors to develop and supply mission-critical technologies for hypersonic vehicles, high-power magnetic wave, and other defense systems.

High-Powered Computing & 5G

Demand for improved, cost-effective cooling solutions in the rapidly growing 5G and cloud computing industries is ever-increasing. KULR’s portfolio of thermal management solutions target air and liquid-cooling of high-performance computing applications such as crypto mining, cloud computing, AI, and AR/VR simulations to maximize performance, energy efficiency and safety. KULR’s proprietary carbon fiber-based suite of thermal interface materials leverage advanced carbon fiber based heatsink technology that offers customers highly customizable, lightweight, and cost-effective solutions with industrial-level reliability due to their high thermal conductivity, lightweight, and low contact pressure.

New Battery Cell Development

KULR started a research and development initiative using carbon fiber structures to produce battery cells with higher energy density and faster charging capabilities. Fast-charging will be the killer app for next-gen batteries. Right now, overheating is a key limiting factor in advancing fast-charging battery technology. There may be a way to solve that problem by using carbon fiber inside the battery cell to reduce thermal and electrical resistance which can dissipate heat more effectively. The R&D initiatives include thicker cathode with higher loading factor, silicon anode, lithium metal anode and solid-state electrolyte development. This is a long-term strategic development for KULR.

Commercial Partnerships

KULR has a long-term technology and developmental partnership with Andretti Technologies (ATEC), the advanced technology arm of racing team Andretti Autosport. The alliance will establish a thermal management testing and design platform for high-performance battery solutions with the highest safety ratings that will be adapted to the technical requirements of Andretti’s racing enterprise with the goal of transferring solutions to mass-market electric vehicle (EV) applications.

New Facility and IT-Systems

KULR relocated in October 2021 to a new facility located at 4863 Shawline St, San Diego, CA. The facility is 3 times larger than the previous facility with adequate room to support the Company’s new automated battery cell testing capability that will launch in Q322 as well as personnel growth. Additionally, the Company installed independently enclosed areas to support the machine shop, testing lab, battery lab, and Fiber Thermal Interface Material (“FTI”) manufacturing lab. KULR has implemented a 5S standard for the entire facility and will seek ISO 9001 certification in June 2022.

KULR has engaged with Managed Solutions to enhance its IT infrastructure and improve all aspects of Cyber Security. As a sub-contractor for DOD programs, it was vital that KULR have state of the art IT systems and controls. The Company believes the best path based on the current scale of the company is to outsource this activity to a professional IT services organization. The result of this activity was an improvement of our NIST score of over 140 points.

EVOLUTION OF KULR

‍

KULR Awarded U.S. Navy Contract to Develop High-Temperature Internal Short Circuit Cells for Enhanced Battery Safety in Critical Applications

HOUSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a provider of advanced thermal management solutions, has been awarded a contract by the U.S. Navy to advance its Internal Short Circuit(ISC) technology to activate at higher temperatures. This development, vital for both military and commercial applications, will support a wide range of safety-critical uses, with particular importance for aviation by enabling the simulation of extreme conditions that better reflect the stringent safety standards of the Federal Aviation Administration (FAA) and European Union Aviation Safety Agency (EASA).

KULR’s ISC devices, originally developed in collaboration with NASA and the National Renewable Energy Laboratory (NREL), induce controlled thermal runaway in lithium-ion cells, offering safer and more accurate testing than conventional methods. With the capability to activate at elevated temperatures, the new ISC devices provide deeper insights into battery behavior under worst-case scenarios, allowing for a precise evaluation of resilience and safety for high-stress environments.

Advantages of High-Temperature ISC Activation

High-temperature ISC activation supports critical advancements in aviation safety by:

  • Accurately Simulating Extreme Conditions: Higher temperature activation mirrors real-world operational stresses, offering precise data on thermal runaway behavior essential for electric and hybrid-electric aircraft.
  • Achieving Greater Consistency with Safety Standards: The advanced ISC testing helps align battery safety development with the rigorous safety expectations of FAA and EASA as electric aviation progresses toward certification.
  • Enhancing Military and Commercial Safety: The technology provides both the U.S. Navyand commercial aviation sectors with tools to rigorously evaluate battery resilience, bolstering mission safety and reliability.

“Our work with the U.S. Navy on high-temperature ISC technology will enhance safety protocols and provide essential data as electric aviation moves closer to regulatory certification and market entry,” said Michael Mo, CEO of KULR Technology. “With these advancements, KULR is well-positioned to support safer, more resilient battery systems across the aviation industry.”

This contract further strengthens KULR’s role as a critical partner in battery safety advancements. Combined with our growing capability to evaluate large-format cells and battery packs during thermal runaway, KULR is uniquely positioned to support the aviation sector in meeting safety standards and advancing safely to market.

______________

KULR NEWS

KULR Xero Vibe Solution Launches on NVIDIA Jetson Edge AI Platform4 hours agoKULR Announces Bitcoin Treasury Strategy6 days agoKULR Announces Immediate Availability of NASA-Certified M35A Battery Cells for JSC 20793 PacksDec 3, 2024KULR Awarded U.S. Navy Contract to Develop High-Temperature Internal Short Circuit Cells for Enhanced Battery Safety in Critical ApplicationsNov 25, 2024KULR Designs for Small Modular Nuclear Fusion ReactorsNov 20, 2024KULR Technology Awarded Key Defense Contract for Leading Missile ProgramNov 14, 2024KULR Reports Record Revenue for the Third Quarter of 2024Nov 13, 2024KULR Technology Group Sets Third Quarter 2024 Earnings Call for Wednesday, November 13, 2024 at 4:30 p.m. ETOct 22, 2024KULR’s Xero Vibe Technology Lands Licensing Partnership with $2.35M DealOct 2, 2024KULR Secures Expanded U.S. Army Battery Contract to $2.4M, Paving Way for KULR ONE Guardian Battery Production in 2025Sep 25, 2024

‍

KULR MANAGEMENT TEAM

MICHAEL MO

CHIEF EXECUTIVE OFFICER

Mr. Mo is a technology entrepreneur and successful investor with over 20 years of experience in technology management, product development, and marketing. From 2007 to 2015, Mr. Mo served as Senior Director of Business Development at Amlogic, Inc. Prior to Amlogic, he was co-founder and CEO of Sympeer Technology, a peer-to-peer network company. Mr. Mo received a Master’s degree in Electrical Engineering from UC Santa Barbara in 1995.

KEITH COCHRAN

PRESIDENT & COO

Mr. Cochran is a value-driven leader offering 25+ years of exceptional high-paced business management and operations expertise. From 1995 to 2019, he worked for world-class EMS, Jabil, Inc. He concluded his 24-year career with Jabil as Sr. Vice President of Global Business Units. Prior to Jabil, Mr. Cochran was Supply Chain Manager for SCI Systems. Mr. Cochran received his Bachelor of Science in Business Operations from DeVry Institute of Technology in 1990.

DR. WILLIAM WALKER

CHIEF TECHNOLOGY OFFICER

Dr. Walker has significant experience in professional and research-related activities focused on thermo-electrochemical testing and analysis of lithium-ion (Li-ion) battery assemblies and related thermal management products designed for space exploration applications. Prior to joining KULR, Dr. Walker was employed by the National Aeronautics and Space Administration (NASA) Johnson Space Center (JSC) where he focused on designing battery assemblies for human spaceflight applications capable of safely mitigating the effects of thermal runaway and preventing cell-to-cell propagation. Dr. Walker received his B.S. in Mechanical Engineering at West Texas A&M University (WTAMU) and Ph.D. in Materials Science and Engineering at the University of Houston (UH).

SIMON WESTBROOK

CHIEF FINANCIAL OFFICER

In 2009, Mr. Westbrook founded Aargo, Inc., a company specializing in financial consulting services to corporations in various tech-related industries. Prior to Aargo, Mr. Westbrook was CFO of Amber Networks, Inc., and the Chief Financial Officer of Sage, Inc. (NASDAQ: SAGI), a Silicon Valley company specializing in flat panel displays. Before Sage, Mr. Westbrook held senior level financial positions at Creative Technology (NASDAQ: CREAF) and Atari Corp (AMEX: ATC). Simon is a Chartered Accountant and holds a Master’s degree in Economics from Trinity College, Cambridge University.

MICHAEL G. CARPENTER

VICE PRESIDENT OF ENGINEERING

Mr. Carpenter was former Director and Safety Officer of Energy Science Laboratories PCM Heatsink Group. He also served as Quality Manager and Facility Security Officer in the Defense Industrial Security Program from 1988 to 1995. Mr. Carpenter received a B.S. in Applied Mechanics from UC San Diego in 1983.

TED KRUPP

VICE PRESIDENT OF SALES AND MARKETING

Mr. Krupp joins KULR with over 22 years of supplying MIL-SPEC computing solutions to U.S. military and intelligence system integrators. Prior to joining KULR, Mr. Krupp served as Vice President of Sales at San Diego based ZMicro, the preferred choice for rugged computing and visualization for deployed and mission critical applications. He expanded ZMicro’s involvement in several platforms, including special operations, ground vehicle systems, tactical datalinks, and next-generation ISR and eventually led ZMicro’s sales department as the company continued to grow in prominence across the Department of Defense and foreign military community. Mr. Krupp completed his undergraduate work in Information Systems at the University of Texas.

ANTONIO MARTINEZ

VICE PRESIDENT OF OPERATIONS

Mr. Martinez joins KULR with over 37 years of leadership and worldwide manufacturing experience in Electronics Manufacturing and Operations. He spent most of his career at Pulse Electronics Corporation in the electronics manufacturing services industry. Most recently he served as Principal Program Manager of Jabil since 2015, managing business operations spanning Quality Assurance Readiness, Large Production Line Transfers, Project Management, Process Improvement with Increased Productivity, and Customer Qualification Support.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND FIVE HUNDRED USD BY SHORE THING MEDIA LLC FOR A ONE DAY KULR AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

CETX

CHECK OUT THE INVESTOR PRESENTATION HERE

_________________________

Hello Everyone,

We anticipate a busy week ahead. We are seeing things heat up right now in the small cap markets.

2 of our last 4 profiles went on to explode triple digits. This could be a sign that things are heating up heading into a Trump presidency.

I don’t know if you remember what happened to the Small Caps during his first term, but the liquidity and interest were massive!

I hope we are gearing up for round two right now. Regardless, there are currently a lot of opportnities surfacing in the markets.

The next company that we want you to turn your attention to is ticker CETX.

First and foremost, the company just completed a 35-1 reverse split on the 26th of November.

This is not always a positive sign for the company but it does potentially present an opportunity.

This company has been around for a while and has been public since 1998. They have just under 350 employees.

They just nailed close to $50 Million in revenues over the last reported 9 month and $59.7Million in 2023.

The recent reverse split basically wiped the float out and the company has recently just lost a significant amount of marketcap.

We have seen some companies recently reverse after taking a bounce.

We really want to watch CETX tomorrow and the rest of the week.

Check out this video first:

Cemtrex Announces Integration of AI Armed Person Detection Feature in Vicon NEXT Cameras

Disruptive AI Analytic for Detecting Armed Persons in Surveillance Footage to be Included in Vicon NEXT Cameras, Primed for Release in First Calendar Quarter of 2025

Hauppauge, NY, Dec. 05, 2024 (GLOBE NEWSWIRE) —  – Cemtrex Inc.(NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, today announced that its subsidiary, Vicon, will integrate an innovative Artificial Intelligence (AI) gun detection feature in its NEXT Cameras, which will be released in the first calendar quarter of 2025, marking a significant milestone in public safety and security technology. This novel detection feature is designed to function on edge devices, offering a low-cost, high-efficiency solution for assistance in the detection of armed persons in surveillance footage and enhancing the capabilities of video management systems to initiate specific responses upon detection.

The launch of this AI feature is part of Vicon’s commitment to developing cutting-edge solutions that meet the dynamic needs of its customers. Armed Person detection uses transformer AI models to detect short and long weapons/firearms that are physically on a person to provide higher accuracy than traditional models. Training is conducted on a wide range of weapons using artificial data as well as real footage with a wide range of body types and positions, and under varied weather and lighting conditions.

The AI technology employs high accuracy to distinguish common objects such as cell phones, wallets, collapsible walking canes, drills, hammers, and tripods, among other objects, to limit false alarms. While performance may be variable across lighting conditions as differences in contrast are required, the technology can detect weapons up to 45 feet from the sensor. Current solutions on the market are generally server-based which are extremely cost prohibitive and difficult to deploy, whereas Vicon’s approach for an edge-based solution, offers a more effective alternative.

“We believe armed person detection is a crucial feature for increasing safety in public spaces such as workplaces and schools,” said Saagar Govil, CEO of Cemtrex. “The feedback received through our collaboration with potential customers showed the technology is an effective tool that organizations can employ as an added layer of security. We look forward to commencing sales of the NEXT Cameras next quarter.”

Vicon, in conjunction with its technology partners, developed this feature to provide real-time alerts and facilitate rapid response, thereby playing a crucial role in enhancing security measures and potentially preventing violent incidents before they occur. The value of integrating gun detection technology into video surveillance systems offers significant advancements in the ability of organizations to protect their premises and the people within them, providing peace of mind in increasingly uncertain times.

Gun violence remains a pressing issue in the United States, with provisional data for 2022 from the Centers for Disease Control and Prevention highlighting the urgent need for innovative solutions:

  • Over 48,000 firearm-related deaths, including nearly 20,000 homicides, were recorded in the U.S.
  • An average, 132 Americans died from a firearm-related injury each day, with hundreds more shot and injured.
  • Guns remained the leading cause of death for children and teens, climbing 87% in the last decade.
  • Recent years have seen a stark increase in school shootings, with 2021, 2022 and 2023 all setting records since at least 2008. There were at least 82 incidents in 2023, but 2022 was one of the deadliest years, with 46 fatalities, according to CNN.

Vicon’s AI gun detection technology aims to contribute meaningfully to efforts to reduce gun violence and its devastating impact on communities across the nation. The Company sees the market opportunity for this feature to be vast, ranging from schools, hospitals, government buildings, retail, to religious institutions.

Cemtrex to Complete 100% Acquisition of Vicon Industries

Brooklyn, NY, Dec. 04, 2024 (GLOBE NEWSWIRE) — – Cemtrex Inc.(NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, today announced that it intends to acquire One Hundred percent (100%) ownership of the entity Vicon Industries, Inc. (VCON), a New York based leading provider of mission critical security and video surveillance systems. This plan, which is expected to close by year-end, will solidify Cemtrex’s position as Vicon’s sole owner, increasing its current stake from approximately 93% to 100%.

Since 1967, Vicon has been a leading manufacturer of mission-critical security surveillance systems. Vicon is focused on providing solutions that are engineered not just for performance and features, but for simplicity in deployment, operation and maintenance. Vicon’s mission is to serve as a valued security technology partner to their customers by reducing security solution complexity, ensuring a superior experience.

According to Markets & Markets, the video surveillance market was valued at USD 30.37 Billion in 2016 and is projected to generate USD $54.42 billion in 2024, with expectations to reach $88.71 billion by 2030. This growth is primarily driven by advancements in camera technology, AI integration, and increasing demand for security solutions across various sectors. The market is set to grow at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2030.

‍

Cemtrex Reports Third Quarter 2024 Financial Results

PUBLISHED

AUG 14, 2024 4:10PM EDT

Q3’24 Industrial Services Segment Revenue Increased 49% to $8.5M; Management to Host Conference Call Today at 5:00 p.m. ET

Hauppauge, NY, Aug. 14, 2024 (GLOBE NEWSWIRE) — – Cemtrex Inc.(NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, has reported its unaudited financial and operational results for the fiscal third quarter ended June 30, 2024.

Key Third Quarter FY 2024 and Subsequent Highlights

  • Revenue for Q3’24 was flat at $14.7 million, compared to revenue of $14.7 million for Q3’23.
    • Security segment revenues decreased 31% to $6.2 million in Q3’24 due primarily to the delay of multiple projects for the segment’s products and services.
    • Industrial Services segment revenues for Q3’24 increased 49% to $8.5 million, on increased demand and additional revenue from the Heisey Mechanical acquisition completed in Q4’23.
  • Revenue for the nine months ended June 30, 2024 increased 14% to $48.7 million, compared to revenue in the prior year period of $42.8 million.
    • Security segment revenues for the nine months ended June 30, 2024, decreased 10% to $23.4 million compared to $25.9 millionfor the nine months ended June 30, 2023.
    • Industrial Services segment revenues for the nine months ended June 30, 2024, increased 50% to $25.3 million compared to $16.8 million for the nine months ended June 30, 2023.
  • Closed $10 million upsized underwritten public offering to conduct operations, increase marketing efforts, invest in existing business initiatives and products, and for the partial repayment of indebtedness.
  • Cash, cash equivalents and restricted cash as of June 30, 2024 was $7.6 million, compared to $6.3 million as of September 30, 2023.

Management Commentary

Cemtrex Chairman and CEO, Saagar Govil, commented on the results: “In the third quarter we continued to see momentum in our segments, sustaining revenue year over year at $14.7 million. Significant demand for AIS products and services drove a 49% increase in revenue to $8.5 million, offset by decreases in Vicon revenue due to the delay of multiple projects and a weaker industrywide demand for security solutions.

“Operating loss for the third quarter was $3.2 million, compared to operating income of $0.1 million a year ago, mainly due to decreased gross profit in our Security segment and increased G&A expenses. The operating loss for the nine-month period was $5.0 million compared to $1.5 million a year ago, despite the higher sales. However, these results include approximately $2 million in one-time expenses related to the May 2024 equity financing, employee related one-time charges and legal expenses. Our goal of achieving a full year operating profit remains and we are working hard to drive revenue and maintain tight cost controls.

“In our Security segment, despite project delays, the team at Vicon continues to push the deployment of new technologies and products with investments into sales and marketing resources that we believe will drive sales over the next several quarters. We also were able to reduce our inventory by over $1 million this fiscal year as we strive to make our operations more efficient. We expect with the launch of the innovative new cloud security platform Anavio, along with new technologies and continued improvements to our core software platform Valerus, there is significant further opportunity to grow revenue and gross margin over the next several quarters.

“Our Industrial services segment delivered another strong quarter on orders from leading companies, building a pipeline of growth that we believe will produce a record year of revenue. We continue to believe with additional orders ahead, AIS has the potential to reach more than 30% annual revenue growth in FY’24, with further room for growth in FY 25.

“During the quarter we took the opportunity to improve our balance sheet with a $10 million upsized underwritten public offering, of which a portion of the proceeds were used to pay off some of our indebtedness. Looking ahead, we are now well positioned for additional growth and to reach our goal to achieve positive operating income in the future. The strengthened balance sheet also provides the ability to explore acquisition opportunities that can enhance our market reach and service capabilities, as we continue to seek long-term value for our shareholders,” concluded Govil.

Third Quarter FY 2024 Financial Results

Revenue for the three months ended June 30, 2024, and 2023 was $14.7 million and $14.7 million, respectively. The Security segment revenues for the three months ended June 30, 2024, decreased by 31% to $6.2 million. The Security segment decrease was due to the delay of multiple projects for the Security segment’s products and services and overall worsening economic conditions in the industry. The Industrial Services segment revenues for the third quarter increased by 49% to $8.5 million, mainly due to increased demand for the segment’s services as well as additional business from the Heisey acquisition completed during the fourth quarter of fiscal year 2023.

Gross Profit for the three months ended June 30, 2024, was $5.9 million, or 40% of revenues, as compared to gross profit of $6.5 million, or 44% of revenues, for the three months ended June 30, 2023.

Total operating expenses for three months ended June 30, 2024, were $9.1 million, compared to $6.4 million in the prior year’s quarter.

Operating loss for the third quarter of 2024 was $3.2 million as compared to an operating income of $0.1 million for the third quarter of 2023. The operating loss was primarily due to a decrease in gross profit in the Security segment and overall increased general and administration expenses.

Net loss for the quarter ended June 30, 2024 was $9.1 million, as compared to a net loss of $1.2 million in the prior year’s quarter.

Cash, cash equivalents and restricted cash totaled $7.6 million at June 30, 2024, as compared to $6.3 million at September 30, 2023.

Inventories decreased to $7.5 million at June 30, 2024, from $8.7 millioat September 30, 2023.

NEWS

Cemtrex Announces Integration of AI Armed Person Detection Feature in Vicon NEXT Cameras1 day agoCemtrex to Complete 100% Acquisition of Vicon Industries3 days agoCemtrex Announces 1-For-35 Reverse Stock SplitNov 21, 2024Cemtrex’s Vicon Industries Unveils the Next Evolution of Camera Technology with NEXT™ Modular Camera SystemNov 12, 2024Cemtrex’s Advanced Industrial Services Awarded $4.7 Million Large-Scale Infrastructure ContractOct 8, 2024Cemtrex’s Advanced Industrial Services Secures $4.5 million ContractOct 1, 2024Cemtrex Reports Third Quarter 2024 Financial ResultsAug 14, 2024Cemtrex to Host Fiscal Third Quarter 2024 Financial Results Conference Call on Wednesday, August 14, 2024 at 5:00 p.m. Eastern TimeAug 9, 2024Cemtrex Reports Second Quarter 2024 Financial ResultsMay 14, 2024Cemtrex to Host Fiscal Second Quarter 2024 Financial Results Conference Call on Tuesday, May 14, 2024 at 5:00 p.m. Eastern TimeMay 9, 2024Cemtrex Reports Second Quarter 2024 Financial ResultsMay 14, 2024Cemtrex to Host Fiscal Second Quarter 2024 Financial Results Conference Call on Tuesday, May 14, 2024 at 5:00 p.m. Eastern TimeMay 9, 2024Cemtrex, Inc. Announces Closing of $10 Million Upsized Underwritten Public OfferingMay 3, 2024Cemtrex, Inc. Announces Pricing of $10 Million Upsized Underwritten Public OfferingMay 1, 2024Cemtrex’s Vicon Industries to Attend ISC West 2024Apr 9, 2024Cemtrex’s Advanced Industrial Services Secures New Orders Totaling $2.1 MillionMar 11, 2024Cemtrex Announces Beta Release of Pioneering AI Gun Detection FeatureMar 6, 2024Cemtrex Issues Shareholder Letter and Provides Corporate UpdateFeb 28, 2024

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVEN THOUSAND FIVE HUNDRED USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY CETX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

NNVC

Targeted Virus-Killing Nanomedicines (PRNewsFoto/NanoViricides, Inc.)

CHECK OUT THE INVESTOR PRESENTATION HERE

‍

___________________________


Hello Everyone,

We have had the good fortune of being able to throw some real explosive profiles in front of you as of late.

We have been seeing some of these small cap companies take off without notice, mirroring a fraction of the volatility that we have been seeing on the crypto markets.

It is highly unusual to profile a 180% winner and a 350% winner back to back.

Don’t say I never got you anything for Christmas.

We have a new profile that we want you to research for Thursday’s session.

You are definitely going to remember this one if you have been a member since the beginning of the year.

This is a company we showed you back in May when it was all the way down at 1.80 the session we asked you to research them. We also brought it to your attention back in mid-June when it was around 2.50.

By mid June NNVC went on a major run, closing green 6 session in a row and exploding all the way to 3.59 for a pure DOUBLE from our first emails in May and 45% in just 3 sessions from our emails in early June.

NNVC certainly had incredible run in early 2024 and has been building a lot of support around it’s current levels.

NanoViricides, Inc. (NYSE American: NNVC) looks well-positioned to be a market disruptor with nontoxic, effective antiviral therapies based on patented nanomedicine technology.

NanoViricides, Inc. (NYSE American: NNVC) is a global leader in the application of nanomedicine technologies to the safe and effective treatment of viruses and their variants INCLUDING drugs against Covid-19, RSV and other respiratory viruses!

Even with a decline since 2022, COVID-19 continues to hospitalize and kill people in the USA – the CDC website states 69,200 hospitalizations and 2,652 deaths since January 1, 2024; the worldwide market size for COVID-19 therapeutics is expected to exceed $16.2 Billion in 2031.

NANOVIRICIDES are better because they destroy viruses and their variants without relying on the patient’s immune system, thereby making them effective for populations that include geriatric and pediatric patients.

Antibodies only bind by two points to the virus, and destruction of the complex requires effective immune function, which is not the case in sick patients..

Vaccines only train the body into producing antibodies against the virus in the vaccine. Antibodies and vaccines are easily overcome by viruses by mutating in the field, hence the need for annual influenza vaccine updates.

NV-387 – A novel broad-spectrum antiviral

NanoViricides, Inc. (NYSE American: NNVC)’s lead drug candidate NV-387 (drug product NV-CoV-2),  a drug that  treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials in healthy subjects with no reported adverse events, even at the highest and repeated dosages. Remarkably, NNVC has been able to develop NV-387 for oral administration already, as well as for injectable and inhalation formulations to enable many modes of use. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.

Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants. Why? Because  no matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective even as the virus mutates to generate variants.

Thus NV-387 and other antiviral drugs designed on the nanoviricides platform can be expected to have decades of  effective usability against the target viruses similar to the life of current antibiotics against bacterial infections but in stark contrast to  current antiviral approaches.

A broad-spectrum antiviral drug such as NV-387 would be a highly desirable drug globally because it  would enable treatment by physicians of patients as soon as they present symptoms of a viral disease without waiting for a test to identify a specific type of viral infection. This is reminiscent of how antibiotics are prescribed, without specific infectious agent identification, relying on the ultra-broad-spectrum of the drug.

NV-387’s Extremely Broad Antiviral is a Host Mimetic That Acts As a Decoy To Attract And Trap Many Diverse Viruses, Preventing the Virus from Replication and Reinfection of Other Cells

Over 90% of human pathogenic viruses are known to use one or more “landing sites” that are in the Sulfated Proteoglycans (“SPG”) family. A successful host-mimetic nanoviricide drug using SPG as the key feature to attract viruses could theoretically be able to attack most if not all such viruses.

NV-387 is designed to mimic SPG and attack the virus as a cell-mimicking decoy. We have accumulated substantial evidence that in lethal viral infection animal studies, NV-387 demonstrated strong antiviral activity against a range of different virus families, exceeding or matching the activity of known approved drug agents.

‍

Superior to Other Treatments???????????

NV-387 was substantially superior to remdesivir in coronavirus infections, using a model for SARS-CoV-2 (COVID) virus, as reported earlier. We believe that NV-387 continues to be one of the most active antiviral drugs against multiple coronaviruses, and that it is a viable clinical candidate for drug development to treat COVID, Long COVID, as well as potentially MERS, SARS, and seasonal coronavirus infections.

In treating Influenza, NV-387 was substantially superior to the three approved drugs, namely Tamiflu®, Rapivab® , and Xofluza® against an Influenza H3N2 lethal lung viral infection study, as previously reported. We believe that NV-387 is expected to possess strong antiviral activity against H5N1 “Bird Flu” as well, given that H5N1 viruses are known to bind to heparan sulfate proteoglycans, and based on the observed broad-spectrum activity of NV-387.

NNVC has also found that NV-387 is capable of completely curing a lethal RSV lung virus infection in animals, leading to indefinite survival of the animals, as reported recently. There is no cure for RSV, and no approved drug for treatment of RSV infection other than the toxic last-resort drug ribavirin.

Moreover, even novel viruses, whether from natural sources or bio-engineered, are expected to be susceptible to NV-387 if they employ SPG for gaining access to human cells to infect and cause disease. Thus, NV-387 could be highly valuable for preparedness against novel viral epidemics and pandemics.

NV-387 could thus be a single drug to treat all of the “tripledemic” viruses (COVID, RSV, FLU ), and more, when so approved!

Finally, NV-387 was at least as effective as the approved drug tecovitrimat (TPOXX®, SIGA), in a lethal intra-digital infection by ectromelia virus in mice. Importantly, a combined drug made from NV-387 and tecovirimat was more effective than either drug alone, indicating NV-387 “plays well” with tecovirimat and acts by a different mechanism.

  • Smallpox poses a significant biodefense threat. Ectromelia virus is a native virus of mice in the poxvirus family and is one of the key animal model viruses for developing smallpox therapeutics. Tecovirimat is an approved drug for treating smallpox infection based on the FDA “Animal Rule”, and is stockpiled by the US “Strategic National Stockpile”. It was mobilized during the recent monkeypox epidemic.
  • It is important to develop additional smallpox therapeutics that work well with tecovirimat and by themselves, since viruses pose the threat of drug escape by mutation; further, in a bio-terrorism scenario, a human-engineered smallpox virus resistant to existing drugs could be a potential threat.
NanoViricides rang the opening bell of the New York Stock Exchange on Aug. 13, 2014. In the front center (left to right) are Meeta Vyas, Anil Diwan and Dr. Eugene Seymour.

‍

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial – Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

PUBLISHED

NOV 15, 2024 6:30AM EST

https://30cfd0ea18af8bb8a3168a9664239a09.safeframe.googlesyndication.com/safeframe/1-0-40/html/container.html

SHELTON, CT / ACCESSWIRE / November 15, 2024 / SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024 with the Securities and Exchange Commission (SEC) on Thursday, November 14, 2024. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000141057824001991/nnvc-20240930x10q.htm).

We reported that, as of September 30, 2024, we had cash and cash equivalent current assets balance of approximately $3.87 Million. In addition, we reported approximately $7.36 Million in Net Property and Equipment (P&E) assets (after depreciation). The strong P&E assets comprise our cGMP-capable manufacturing and R&D facility in Shelton, CT. The total current liabilities were approximately $1.63 Million. In comparison, as of June 30, 2024, we had cash and cash equivalent balance of approximately $4.8 Million, P&E assets of approximately $7.51 Million (after depreciation), and total current liabilities of approximately $1.36 Million.

The net cash utilized in the reported period for operating activities was approximately $2.6 million that included certain non-recurring expenditures including R&D expenditures in preparation for a Phase II clinical trial application of approximately $1 million. We raised approximately $1.71 million net of commission and certain expenses in an At-the-Market offering (“ATM”) in the reported period.

Subsequent to the reporting period, we raised approximately $0.63 million net of commission and certain expenses in an At-the-Market offering (“ATM”). With this raise and an available line of credit of $3 million provided by our founder and President Dr. Anil Diwan, we have approximately $7.6 million (approximately $6 million net of current liabilities) available for cash operational expenses going forward. As such, we reported that we do not have sufficient funding in hand to continue operations through November 14, 2025, for our planned objectives that include (i) a Phase II clinical trial of NV-387 for MPOX infection in Central Africa and (ii) a Phase II clinical trial of NV-387 for RSV indication in the USA.

NV-387 – Progressing Towards Phase II Clinical Trial

We have made significant progress in the regulatory advancement of NV-387. A Phase Ia/Ib clinical trial in healthy subjects was completed with all subjects discharged as of end of December, 2023. There were no adverse events reported. We are now awaiting a final report of this Phase I clinical trial.

Additionally, we have made significant progress towards initiating Phase II clinical trial of NV-387 for the treatment of MPox infection in Central Africa. The MPox Clade 1/1b infection has been declared a Public Health Emergency of International Concern (PHEIC) by the WHO. Spillover cases have occurred in several Eastern and Western countries already, raising the probability that the epidemic may spread more widely, although the current MPox virus is not as communicable as coronaviruses. The MPox Clade 1/1b has a substantially greater fatality rate than COVID, at 3-4%, and it has been disproportionately affecting pediatric populations.

There is currently no drug available for the treatment of MPox infection. A drug approved for Smallpox/Mpox and stockpiled by the US Strategic National Stockpile, namely tecovirimat (TPOXX®, SIGA), was found to be ineffective for the treatment of the MPox infection in a clinical trial co-sponsored by NIH/NIAID. A vaccine developed for Smallpox, Jynneos (Bavarian Nordic) is being deployed but is in short supply. Its clinical utility for MPox Clade 1/1b is not known.

NV-387 A Potentially Revolutionary Antiviral Drug that the Viruses are Unlikely to Escape

Our host-mimetic, direct-acting, broad-spectrum, antiviral agent. NV-387 was found to have activity that surpassed the activity of known agents in lethal virus infection animal model trials for COVID, RSV, Influenza, and Mpox/Smallpox.

In fact, we found that NV-387 treatment possibly completely cured the lethal RSV infection in mice, based on indefinite survival of the animals with no lung pathology. There is currently no treatment for RSV infection. In particular, pediatric RSV infection treatment is an unmet medical need that we believe is of critical importance. Pediatric RSV treatment itself is expected to be a multi-billion-dollar market in the USA alone.

NV-387 treatment was found to be substantially superior to three approved anti-influenza drugs, namely, oseltamivir (Tamiflu®, Roche), peramivir (Rapivab®, Biocryst), and baloxavir (Xofluza®, Shionogi/Roche).

Additionally, NV-387 also demonstrated activity against lethal poxvirus infection animal models that was on par with or superior to the approved drug tecovirimat (TPOXX®, SIGA).

NV-387 acts by a mechanism that is significantly different compared to the tested existing antiviral agents for COVID, Influenza and Poxviruses.

This demonstrated broad-spectrum activity of NV-387 against widely varying viruses is because NV-387 is designed to attack the virus particle by mimicking sulfated proteoglycan (S-PG) feature, and all of these viruses are known to utilize heparan sulfate proteoglycans for gaining cell entry.

Further, for all of these tested viruses, even as the virus genome changes in the field, NV-387 is expected to continue to be effective, and the virus would be highly unlikely to escape NV-387. This is because despite all of the genomic changes, the virus continues to use HSPG, as is well known. Thus NV-387 solves the greatest problem in antiviral countermeasures; the problem of virus escape. Viruses are known to escape all of the current antiviral tools that include vaccines, antibodies, and small chemical drugs.

Thus we anticipate that NV-387 would revolutionize the treatment of viral infections reminiscent of how penicillin revolutionized the treatment of bacterial infections.

NV-387 Regulatory Strategy

In the ensuing year, we plan on advancing NV-387 into Phase II clinical trials. In addition to the Phase II clinical trial to assess effectiveness of NV-387 in treating MPox infections, we are also planning to advance NV-387 into a Phase II clinical trial for treatment of RSV infection in adults as part of the regulatory process required for registration of the drug for the treatment of pediatric RSV infection.

We plan on advancing the regulatory processes for NV-387 registration for other indications including Influenza and COVID via partnerships and non-dilutive funding.

As we meet the milestones, we believe we will be able to raise financing for further regulatory activities for NV-387 registration via non-dilutive grant funding, partnership revenues, as well as equity-based funding.

‍

bindingimage

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs

SHELTON, CT / ACCESSWIRE / September 26, 2024 / NanoViricides, Inc. (NYSE American.:NNVC) (the “Company”), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it has now obtained a right of first refusal (ROFR) for all antiviral drug developments from the R&D firm TheraCour Pharma, Inc.(“TheraCour”).

NanoViricides has signed a broad Memorandum of Understanding Agreement (MoU) with TheraCour encompassing all antiviral drugs developments on September 23, 2024, an important step that provides the Company certain intellectual property rights for developing treatments against any viral infections.

NV-387, the Company’s lead drug, is proving to be a revolutionary drug that has demonstrated strong effectiveness, surpassing existing drugs, against a number of distinctly different types of viruses in animal studies. With this MoU in place, the increasing number of antiviral indications of a broad-spectrum drug such as NV-387 can be quickly and easily discovered and added by the Company to its portfolio of drugs in its development pipeline.

In addition to NV-387, certain “Trojan Horse” drugs that can completely cure most viral infections by attacking the virus lifecycle in multiple ways have been developed by the Company. This MoU expands NanoViricides Inc’s abilities to opportunistically and rapidly develop such drugs to treat viral infections of public health importance, even for those viruses that don’t exist today and cannot be predicted.

The new MoU provides NanoViricides with the ability to rapidly progress in such new endeavors and provides the important intellectual property rights to further develop multiple drug candidates towards a multitude of antiviral applications, many of which may have been previously considered to be intractable.

The MoU also codifies the process by which the two parties negotiate licenses to specific antiviral fields. As in the past, a license would not be restricted to a single drug, but rather would encompass all drugs that can be conceivably applicable with the R&D performed against the licensed field of antiviral application.

The revolutionary nanoviricide technology resulting in host-mimetic, direct-acting antiviral drugs is opening up a new era of treating viral infections just as penicillin opened up a new era and revolutionized the treatment of bacterial infections, enabling “one drug – many bugs” model instead of the current “one bug – one drug” model. NV-387, an example of the capabilities of nanoviricide technology, was developed in 2020 in response to the COVID pandemic and has completed a Phase I human clinical trial successfully. The Company is now planning for NV-387 to enter into Phase II clinical trials for evaluation of its efficacy against several viral diseases that include RSV, Influenza, Bird Flu, COVID, as well as MPOX/Smallpox infections.

What is a “nanoviricide”?

A “nanoviricide” is a uniform polymer that self-assembles into nanoscale droplets called “micelles”, that carries on its surface mimics of the cell-side receptor of the virus, and that hides in its belly lipid tentacles. It can also hold other guest APIs in its belly if needed. The nanoviricide thus “looks like” a cell to the virus, and the virus is fooled into binding it. Once the virus binds, we believe, the flexible and shape-shifting nanoviricide micelle would spread over the virus particle by virtue of merging the lipid tentacles that are hidden in its belly into the virus surface, in a well known process called “lipid-lipid mixing.” We believe this would destabilize the virus particle, uproot the viral glycoproteins required for binding to and entering the host cell, and thus render the virus particle incapable of infecting a cell.

What are “Trojan Horse” nanoviricide drugs?

A nanoviricide can hide in its “belly” (i.e. encapsulates) one or more drugs that can attack the virus in other ways. The nanoviricide holding the drugs is expected to attack the virus particle itself and thus block the virus from infecting cells. We call this “Re-Infection Inhibition”. The encapsulated drug can be protected from host’s metabolism and delivered into infected cells to block the virus from replicating inside the cell. If both of these parts of the virus lifecycle are blocked, the viral infection would be cured, except in the case of viruses that create latency. A different encapsulated drug can also be delivered to attack the virus in its latent or dormant phase, although this has been a topic of scientific research rather than drug development as of now. Thus the “Trojan Horse” capability of a naoviricide enables developing drug that can cure most virus infections, and can be developed in the future to cure even viruses that cause latency such as herpesviruses and HIV/AIDS that are non-curable at present.

TheraCour is founded by and substantially owned by Dr. Anil R. Diwan, who is also the Company’s co-founder. Dr. Diwan recused himself from the MoU discussions that were led by the Company’s Board of Directors in conjunction with legal advice from the Company’s counsel.

‍

NEWS

‍

MANAGEMENT

‍

Anil R. Diwan, PhDExecutive Chairman, President

Dr. Diwan has been President and Chairman of the Board of the Company since its founding in 2005 Dr. Diwan spearheaded the efforts for the Company’s 2013 uplisting from the OTC Markets to NYSE-American. Dr. Diwan has led several of the Company’s financing efforts since 2010.

Dr. Diwan invented novel polymeric micelle-based nanomedicine technologies as early as 1991. Dr. Diwan is a prolific inventor and a serial entrepreneur. Prior to co-founding NanoViricides, Inc., he has founded TheraCour Pharma, Inc., a privately held company focused in nanomedicines and cell-targeted drug delivery, and AllExcel, Inc., a company with diverse portfolios including nanomedicines, small chemicals, device technologies, as well as informatics. He has won several NIH SBIR (small business innovation research) grant awards. Anil holds a Ph.D. from Rice University, TX, a B.Tech. from Indian Institute of Technology, Mumbai (IIT-B), India, and has consistently held high scholastic ranks and honors. Dr. Diwan has over 25 years of Bio-Pharmaceutical R&D experience with over 20 years as an entrepreneur.

He has several patents issued internationally resulting from three fundamental international patent applications. Under Dr. Diwan’s leadership, NanoViricides, Inc. has been able to keep both administrative and R&D costs at extremely low levels while robustly expanding the drug pipeline every year. Dr. Anil R. Diwan was recognized as “Researcher of the Year” by BusinessNewHaven, a Connecticut Area Business Journal, in 2014.

Ms. Meeta R. Vyas, MBA (Fin.), BS (Chem. Eng.)

interim Chief Financial Officer

Ms. Vyas is known as a strong leader with board level experience and successful achievements as a Senior Executive in a broad range of entities including publicly listed corporations, non-revenue generating entities, and medium to large size companies. Meeta has over twenty-five years of experience in performance and process improvement of both publicly listed companies and non-revenue producing entities, in areas ranging from Finance and Operations to Strategy and Management. Meeta holds the distinction of being the first Indian woman to be named CEO of a publicly listed US corporation, Signature Brands, Inc., best known for “Mr. Coffee” and “Health-O-Meter” brand products. As CEO, acting COO and Vice Chairman of the Board of Signature Brands, Inc., she was responsible for the development and implementation of a turnaround plan, resulting in a return to profitability and growth within a short period of time. Later, as the CEO of the World-Wide Fund for Nature – India (WWF-India) and then as a Vice President of the National Audubon Society (USA), both non-revenue generating entities, Meeta successfully raised unrestricted funding that significantly exceeded annual requirements and also instituted financial processes to measure a variety of performance metrics. Earlier in her career, she was responsible for designing the strategy and initiating the implementation plan for the highly successful information technology outsourcing program at General Electric (GE). Also at GE, Ms. Vyas ran GE Appliances’ Range Products business unit having revenues exceeding $1 Billion where her team doubled operating income in less than two years. Prior to that, as a management consultant with McKinsey and Company, she served publicly listed companies in chemicals, industrial, and technology markets, primarily focusing on growth strategies, valuations, post-merger integrations, and logistics operations. Meeta is married to NanoViricides, Inc. President and Chairman Anil R. Diwan.

Ms. Vyas holds a MBA in Finance from Columbia University’s Graduate School of Business, and a BS in Chemical Engineering from the Massachusetts Institute of Technology.

NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.

‍

Randall W. Barton, PhD.Chief Scientific Officer – Consulting

Dr. Barton has experience in drug discovery and development of both small molecule and biological drug candidates in virology, immunology, inflammation, and cardiovascular diseases in the pharmaceutical and biotech industry as well as academic research and teaching experience. Most recently, he was Vice-President of Drug Discovery at A&G Pharmaceuticals, a biologics and diagnostics company. He retired at the Director level after 20 years at Boehringer Ingelheim Pharmaceuticals. During his time at Boehringer Ingelheim he performed drug development pre-clinical studies on nevirapine (Viramune), a non-nucleoside inhibitor of HIV reverse transcriptase and an important HIV drug.

Prior to joining Boehringer Ingelheim, he was on the faculty at the University of Connecticut Medical School where he was the recipient of an NIH Career Development Award conducting research and teaching in immunology. Dr. Barton has authored over 80 scientific publications, and has been the principal investigator leading to 5 patents. He has a Ph.D. in biochemistry from the University of Tennessee at Oak Ridge National Laboratory and a B.A. from Indiana University.  

Jayant Tatake, PhD.

Vice President, R&D

Jay Tatake is an organic chemist with over 25 years of experience in Research and Process Development of fine chemicals. His experience encompasses production scale-up, and large scale manufacture of raw materials for pharmaceuticals. Before joining NanoViricides, Inc., he was Assistant Director of Analytical R&D at Interpharm, Inc. Prior to that, he was Director of Analytical Services at Pharmax Group, Inc. Dr. Tatake has several years experience in Analytical methods development and Quality Control in cGMP environment. His experience includes bio-analytical methods development. Prior to Pharmax Group, he was in the Pharmacology Department, University of Connecticut Health Center, where he synthesized and developed novel bio-conjugates for bio-diagnostics applications.

Jay has a Ph.D. from Department of Chemical Technology, University of Bombay. He is a member of American Chemical Society (ACS). He has published several papers in leading journals and is a co-inventor of several patents.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVEN THOUSAND USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY NNVC AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.